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A stroke or cerebrovascular accident is one of the leading causes of death worldwide. Ischemic 
stroke, the most common form, is caused by a blockage in blood supply to the brain. It triggers 
a cascade of pathological events including inflammation, excitotoxicity and release of free 
radicals that lead to cell death. To date, drug therapies have attempted to target the loss of nerve 
cells. These therapies are collectively known as neuroprotectants. However, these therapies 
have failed to translate into the clinic. The only FDA-approved treatments for acute stroke are 
either thrombolytic agents such as alteplase and tenecteplase that have a therapeutic window 
of 4.5-6 h, or endovascular stent clot retrieval devices that can be used within 24 h. While these 
work well, they are only useful in approximately 15% of all stroke cases, which is why there 
is a compelling need to find new stroke treatments.   
Recently, tumour suppression drugs have proven their ability in promoting microtubule (MT) 
equilibrium and growth cone development. In preclinical studies, the cancer treatment 
medications taxol and epothilones showed a capacity to stabilise microtubules (MTs). 
Epothilones have more advantages than taxol, such as the ability to cross the blood-brain barrier 
and induce less tissue toxicity. Epothilones represent a potential pharmacological treatment to 
modulate functional recovery outcomes after a stroke. Although the pharmacokinetics and 
pharmacodynamics of epothilone and taxol are available, more data needs to be collected to 
clarify their therapeutic potential. It is important to accurately test whether isotypes of these 
drug families can reduce drug-related side-effects, and to find the most appropriate 
pharmaceutical preparation for axonal growth and synaptic rewiring for functional recovery. 
To date, there has not been any trial to use a MT stabilizing agent in an animal stroke model. 
This project’s general aim is to test the effect of systemic and local administration of epothilone 
D on functional recovery and axonal growth in a mouse stroke model. The D isotype was 
investigated because it is a more potent microtubule stabilizer than other epothilone isotypes. 
In this project adult male mice were randomly distributed among 6 groups (n=7 per group). 
Stroke was induced by photothrombosis in the treatment groups, while sham animals received 
the same procedure without a photothrombosis reaction. Epothilone D or vehicle was 
administered either as weekly 1.5 mg/kg intraperitoneal injections for 3 weeks or locally into 
the stroke cavity in the form of a hyaluronan/ heparin gel (5 nM). Animals were tested on grid 
walking and cylinder tasks for 7 weeks before euthanasia. Brains were collected for histological 
assessment. It was evident that epothilone D administered systemically significantly reduced 
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the number of forelimb foot faults contralateral to the stroke injury side from 6 weeks post-
stroke in a gridwalking task compared to mice receiving vehicle instead of epothilone D 
(P<0.05). Furthermore, axonal sprouting in the motor and premotor cortexes (assessed using 
neuroanatomical labelling following injection of the tract tracing dye biotinylated dextran 
amine, BDA) was improved in systemic epothilone D-treated stroke-affected mice in 
comparison to vehicle-treated stroke-affected animals (P=0.001). However, animals which 
received local infusion of epothilone D in the stroke cavity failed to show signs of improved 
behavioural outcomes or a significant change at the level of axonal sprouting. These results are 
promising regarding the potential use of epothilone D and other MT stabilizing drugs in stroke 
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Stroke or a cerebrovascular accident is the leading cause for adult disability (Abbott et al., 
2017). A stroke is caused by a blockage in blood supply to the brain. Within minutes of blood 
cessation, glucose and oxygen levels become depleted in tissue supplied by the affected vessel, 
resulting in suppression of adenosine triphosphate (ATP) production and an imbalance in 
cellular homeostasis. This triggers a cascade of pathological events including inflammation, 
excitation and release of free radicals that leads to cell death (Xing et al., 2012). To enhance 
the outcome of stroke, targeting neurons to reduce extensive cellular loss or to confer 
neuroprotection is considered the main target for the existing treatment approaches by 
investigating molecular and cellular events (Upadhyay, 2014; Nozohouri et al., 2020). 
Neuroprotective strategies using inhibitory receptor mechanisms, cytokines or epigenetics are 
the main research field in the molecular approaches. Regarding the cellular response to injury, 
neuroprotection trials that target a reduction of cellular loss are considered the main research 
focus. However, these approaches are still in the preclinical trials and it is difficult for them to 
be translated into clinical trials. For now, the only drugs approved by the Food and Drug 
Administration (FDA) for stroke treatment are potent anticoagulants, such as alteplase and 
tenecteplase. However, the limitations for the uses of these drugs are represented by the narrow 
therapeutic window of administration, as the time is limited for 4-6 h after the incidence of 
stroke, and the increased incidence of intracranial hemorrhages if not followed by surgical 
removal of the blood clots from the arteries which is known as thrombectomy (Campbell et al., 
2018). Recently, endovascular stent clot retrieval devices have been developed, which 
extended the therapeutic window to 8 h (Kim et al., 2006). However, these approaches are not 
necessarily curative, which means that stroke survivors can still express signs of neurological 
deficits. Only 25% of survivors will be able to recover and perform normally, leaving the other 
75% in need of intensive special treatment such as rehabilitation as a result of disability 
(Dobkin, 2005).  Due to these limitations, new methods need to be designed.  
Another approach for stroke treatment that is still under investigation is to target the 
cytoskeleton of the affected neurons. It is a well-established fact that after ischemia the 
cytoskeletal component of the cells undergoes degeneration (Malinak and Silverstein, 1996; Li 
et al., 1998) have demonstrated that brain hypoxemia resulted in distribution and reduction of 
microtubule (MT)-associated proteins in the affected neurons within the first 8 hours after 




using MT stabilizing agents as an attempt to reduce the destruction or promote axonal sprouting 
(Brunden et al., 2010; Brizuela et al., 2015; Sandner et al., 2018). Epothilones (B and D) and 
taxol are the most used MT stabilizing drugs. The experiments in this thesis are novel because 
it is the first to assess the relation between stabilization of MTs and the functional recovery 
after motor cortex stroke in mice.  
In general, stroke is divided into two categories, ischemic and haemorrhagic. Ischemic stroke 
represents almost 85% of all stroke cases occurring every year (Khaku and Tadi, 2020). It 
occurs when there is a marked reduction in the blood flow in the brain region.  Haemorrhagic 
stroke occurs when there is a blood leak from a blood vessel or abnormal vasculature (Abbott 
et al., 2017). In the research in this thesis, ischemic stroke is being studied as it accounts for 
the majority of the cases, requiring extensive effort to understand the pathological mechanisms 
and thus minimizing the effect of brain ischemia events. 
1.2 Epidemiology 
According to a study, stroke affects almost 13.5 million new people each year globally, and 
about 5.5 million die as a result (Johnson et al., 2019). Half of these deaths are related to 
ischemic stroke. About 9.5 million of these new cases are related to ischemic stroke, while 
almost 4 million are related to haemorrhagic stroke. Statistically, more that 80 million people 
currently living have experienced stroke at least once; 40% of these are in individuals aged 
under 70 years or age (Johnson et al., 2019). In ischemic stroke, 52% is the incidence in males 
while the rest (48%) occurred in females. These numbers are mirrored for haemorrhagic stroke 
(Johnson et al., 2019). However, the mortality rate is higher in females with a percentage of 
51% compared to males with mortality rate of 49% (Thrift et al., 2014). In the United States, 
there are 800,000 new cases every year, of which 87% are diagnosed as an ischemic stroke, 
with an estimated socioeconomical impact of 70 billion USD (Ovbiagele and Nguyen-Huynh, 
2011). The prevalence of stroke in the USA is estimated to be 3% of the adult population, with 
the incidence rate doubling for each 10 years after 55 years-of-age (Ovbiagele and Nguyen-
Huynh, 2011). A study conducted between 1995 and 1998 on the distribution of stroke-related 
death in the USA showed that there are about 98 deaths due to ischemic stroke in black males 
compared to 93 deaths in black females per 100,000 population over the period of study (Ayala 
et al., 2001). However, in the Hispanic population, this ratio was decreased to 41 and 38 deaths 




In New Zealand, there are about 9,000 - 10,000 new cases each year, and about 2,000 - 2,500 
cases have death as an outcome (Johnson et al., 2019), with an overall annual cost of 700 
million NZD (Feigin et al., 2007). The incidence rate among European New Zealanders, Pacific 
Islander and Māori populations is 19%, 54%, and 38%, respectively (Feigin et al., 2007). 
Moreover, the average age for the first incidence of stroke amongst the same population was 
76 years in European New Zealanders, 65 years in Pacific Islanders, and 61 years in Māori 
(Feigin et al., 2007).  Feigin et al. (2020) have proposed a wider scale study to measure the 
burden of stroke and transient ischemic attack (TIA) on the New Zealand society. The 
objectives of this study were to obtain a precise estimation of the fatality and incidence rate of 
stroke over 40 years of investigation, and the same parameters over 10 years for TIA. Also, the 
study aimed to establish the outcomes of stroke and TIA in matters of severity, disability, and 
related health quality impact (Feigin et al., 2020). However, this study is limited in its ability 
to track the changes in stroke incidence over the proposed period due to the constant changes 
in the definition of stroke by the World Health Organisation (WHO) and American Heart 
Association (AHA). Therefore, an additional objective was to reflect the ongoing modifications 
for stroke and TIA definitions over the epidemiological studies of stroke and TIA in New 
Zealand. One year before this proposal, a study by Ranta (2018) showed that, in comparison to 
other developed countries, New Zealand has a higher age-adjusted incidence rate of 119 per 
100,000. New Zealand also has a higher mortality rate compared to Australia (Ranta, 2018). In 
conclusion, the incidence rate is estimated to be higher in Māori and Pacific Islanders compared 
to European New Zealanders, and this higher incidence rate is reflected in the mortality rate of 
these populations. In contrast, the incidence and mortality rate in Asian New Zealanders are 
still unknown and need further investigation. 
1.3 Risk Factors 
Risk factors are defined by the WHO. They include anything that will increase the possibility 
of developing a disease or injury. The risk factors for stroke are classified into modifiable and 
non-modifiable factors. Non-modifiable risk factors include race, age, gender and genetics, and 
the most important modifiable risks are blood pressure, heart disease, diabetes, elevated lipid 
levels, obesity, smoking, and excessive alcohol consumption (Choudhury et al., 2015). 
Modifiable risk factors were found to be associated in 90% of the stroke incidence (O'Donnell 




and ten modifiable risk factors. These factors include the previously mentioned ones in addition 
to diet, waist to hip ratio, and the regularity of physical activity.  
Non-modifiable risk factors are those that cannot be reversed or reduced. Hence, they are also 
called non-reducible risk factors. In stroke, ethnic and gender disparities are considered as a 
major non-modifiable risk factor. For instance, as mentioned previously, Māori are twice as 
likely to have a stroke compared to European New Zealanders (Feigin et al., 2007). Gender 
also has an impact over the incidence of stroke. Males are more prone to have an ischemic 
stroke, females have a higher mortality rate, and female survivors have the worst outcome 
(Labiche et al., 2002; Feigin et al., 2010; Kim et al., 2010). Genetic predisposition plays a 
major role as a non-modifiable risk factor. Cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy, usually called CADASIL, is an inherited 
condition that affects small cerebral blood vessels. It is a result of a NOTCH3 gene mutation 
(Markus, 2011). Ischemic stroke is the most common manifestation of CADASIL, occurring 
in about 60-85% of patients that hold this condition (Chabriat et al., 2009). Cerebral autosomal 
recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL; a result 
of a mutation of the HTRA1 gene), which is the recessive form of CADASIL, also affects small 
blood vessels. People having CARASIL are 50% more likely to have an ischemic stroke during 
their life (Fukutake, 2011). Another important genetic predisposition related to stroke is 
mitochondrial encephalo-myopathy, lactic acidosis, and stroke-like episodes (MELAS). The 
mutation for this condition occurs on the MT-TL1 gene, resulting in the inability of the 
mitochondria to produce sufficient energy to meet the high demand of different organs 
including the brain, resulting in stroke-like episodes in more than 25% of the affected 
population (El-Hattab et al., 2015).  Sickle cells, Fabry's disease, homocystinuria, Marfan 
syndrome, Ehlers-Danlos syndrome type IV, and pseudoxanthoma elasticum are all examples 
of genetically inherited diseases that cause stroke by affecting large arteries, small arteries, 
cardio embolism, or atrial dissection (Dichgans, 2007).  Generally, any genetic inherited 
disease that can affect blood flow or energy production holds a potential to be a genetic risk 
factor for stroke.  
The main modifiable risk factors for stroke are hypertension, smoking and increased alcohol 
intake. However, to understand the variation of these factors among ischemic stroke types, the 
differentiation among the etiological causes is necessary as ischemic stroke is subdivided into 




1.3.1 Ischemic stroke types 
According to the trial of org 10172 in acute stroke treatment (i.e., the TOAST studies in the 
U.S population), definitions were devised to subdivide the patients with ischemic stroke into 5 
main etiological classes (Adams et al., 1993). In these studies, the main focus was to study the 
effect of org 10172 which is a low molecular weight heparinoid (danaparoid sodium/Orgaran) 
that supresses the expression of the Stuart–Prower factor (i.e., factor X) that is related to the 
coagulation cascade (Investigators TOAST, 1998). The first TOAST class is called large artery 
atherosclerosis (LAA), which is the most common subtype of ischemic stroke. LAA occurs 
when there is a focal impairment in the tunica intima of blood vessels (Cole, 2017). About 40% 
of ischemic stroke patients were diagnosed with LAA, with the carotid and cerebral arteries 
being the most affected blood vessels. The second recognised subtype is called cardio-
embolism (CE) (Arboix and Alió, 2011). It is caused by a heart-originated embolism that has 
transferred to the brain, and it is a result of a heart anomaly (e.g. valve disease, shunts, 
endocarditis) (Arboix and Alió, 2011). Nonvalvular atrial fibrillation increases the chance of 
stroke by five times and is responsible for almost 25% of strokes affecting people over the age 
of 80 (Paciaroni et al., 2007). Small artery occlusion (SAO) was defined as the third type. This 
is also known as a lacunar stroke or as small subcortical brain infarcts. The most common site 
for this type is small arteries supplying deeper white matter (Bamford and Warlow, 1988). The 
fourth ischemic stroke subtype is unusual and is determined by reasons such as vasculopathy 
unrelated to atherosclerosis, coagulopathy or haematological disorders (Adams Jr et al., 1993). 
The fifth subtype is stroke with an undetermined reason. It might be undetermined because 
there was no evidence of the cause, or due to the presence of more than one probable cause 
simultaneously (Kolominsky-Rabas et al., 2001). 
1.4 Stroke Pathology 
The pathogenesis of ischemic stroke starts when there is a marked decrement of the supplied 
oxygen and glucose required by neurons to perform normally. Depending on the magnitude of 
the decrement of blood supply, ischemic stroke can be further sub-classified as being either 
focal or global. Focal ischemia is when a distinct part of the brain is affected by the reduction 
in blood flow, whereas global ischemia is when the whole brain or cerebral lobe is affected 
(Bacigaluppi et al., 2010), for instance following cardiac bypass surgery. For each ischemic 
stroke site there are two distinct zones: the ischemic core and the penumbra (see Figure 1.1). 




and endothelial cells of blood vessels, as a response to the injury. Apoptosis will follow if the 
injury persists (Li et al., 1997). Cell death also affects the cells in the penumbra region. Here 
the cells are affected by the reduction of blood flow to a level that causes cessation of electrical 
conduction, yet the cell wall is still maintained keeping ion homeostasis (Memezawa et al., 
1992). The size of the ischemic core and penumbra are mainly dependent on the factor of time. 
In other words, the longer it takes to restore normal blood perfusion, the bigger the size of the 
ischemic core, and the smaller the size of the penumbra (Figure 1.1). The reduction of the blood 
flow will initiate a cascade of pathological events which activate the excitatory 
neurotransmitters synchronized by cell death. This is triggered by the activity of free radicals 
and inflammation. 
 
Figure 1.1: Diagram showing the inverse relationship between the size of the ischemic core 
(yellow) and the penumbra (dark blue) in the mouse brain. It also illustrates the progression of 
stroke expansion with time. Adapted from (Dirnagl et al., 1999). 
 
1.4.1 Excitability 
Excitotoxicity is a term that refers to the pathophysiological events connecting the activation 
of excitatory neurotransmitters, especially glutamate, which ultimately ends in neuronal cell 
death. Glutamate is the most abundant fast neurotransmitter that is found through the entire 
central nervous system (CNS). The first documented toxic effect of glutamate was reported in 
1957 by Lucas and Newhouse. They reported that parenteral administration of glutamate 
resulted in a degeneration of the inner layer of the retina in mice (Lucas and Newhouse, 1957). 
A decade later, in 1969, Olney and Sharp showed that the subcutaneous administration of a 
relatively high dose of monosodium glutamate produced acute cell death in hypothalamic 
regions (Olney and Sharpe, 1969). After that, Olney and Gubareff set up the basis for what 




glutamate which can induce damage in areas that lack an adequate protection of the blood-
brain barrier (BBB) (Olney and Gubareff, 1978). As discussed earlier, and extensively 
discussed through the literature using in vivo and in vitro experimental approaches (Olney and 
Gubareff, 1978; Goldberg et al., 1987; Rothman and Olney, 1995), excitotoxicity occurs when 
there is an overflow of glutamate that leads to accumulation of calcium, sodium and potassium 
ions. This in turn results in compromised neuronal cell wall integrity and ultimately leads to 
cell death. In ischemic stroke, the negative influence of excitotoxicity also has been addressed. 
It was found that ischemic brain injuries or cardiac arrest will elevate the glutamate 
concentration, resulting in an induction of extensive cell death in ischemic regions of the brain 
(Siesjo et al., 1989; Szydlowska and Tymianski, 2010; Puyal et al., 2013).   
The process of glutamate-mediated cell death begins with a sudden depletion of adenosine 
triphosphate (ATP), which leads to the failure of ion pumps expressed on cell membranes, and 
impairment to the membrane potential. A change in cell membrane potential will result in 
depolarisation of neurons and an increase of intracellular Ca2+ levels.  This increase in Ca2+ 
will trigger the release of glutamate and activation of both ionotropic and metabotropic 
glutamate receptors. The activation of these receptors will increase the Ca2+ concentration 
intracellularly in the postsynaptic neuron. In other words, ATP depletion leads to an increase 
of Ca2+ concentration, which will lead to increase in glutamate levels in the extracellular space, 
and eventually will lead to further increase in Ca2+ inside the neurons, and the cycle continues, 
where Ca2+ ions are increasing inside the postsynaptic neurons, while glutamate is being 
accumulated in the extracellular space (Figure 1.2).  
In addition, the failure of ATPase pumps expressed on the astrocyte wall will lead to the 
accumulation of Ca2+, Na+ and K+ ions inside the astrocytes. At the same time, there is a marked 
failure in the glutamate reuptake mechanism due to the ischemic effect. The accumulation of 
these ions will lead to the reversal of the uptake mechanism, which results in glutamate 
accumulation in the extracellular space (Moro et al., 2005). This accumulation of glutamate 
extracellularly will lead to excessive stimulation of NMDA receptors and will result in the 
influx of a huge amount of Na+ and Cl- ions. The total ion influx greatly exceeds the sum of 
efflux K+ ions. The result will be an increase in intracellular osmolarity, and water molecules 
will follow leading to cell swelling and oedema, eventually ending up with neuronal lysis 






Figure 1.2: Pathophysiology of excitotoxicity in ischemic injury (adapted from (Dirnagl et al., 
1999; Song et al., 2020). Glu; Glutamate, ROS; reactive oxygen species, RNS; reactive 
nitrogen species 
On the other hand, a disturbance in ion concentration can lead to cell death by means of MT 
depolymerization. Nakamura et al. (1993) investigated the role of Ca2+ on the MT component 
of neurons in the gerbil brain by inhibiting Ca2+ entry and assessing immunohistochemical 
staining of the MT associated protein 2 (MAP-2). The results of this study showed that use of 
dizocilpine (an NMDA antagonist), nicardipine or nimodipine (a Ca2+ channel blocker) reduced 
the Ca2+ concentration inside the cells 5 minutes after ischemia to 30 minutes after reperfusion. 
The MAP-2 reaction was reduced in both treatments. However, the MAP-2 reaction was 
maintained in groups with pre-ischemic treatment with dizocilpine, suggesting that Ca2+ can 
affect the stability of MTs and thus the cell itself (Nakamura et al., 1993). Furukawa et al. 
(1995) studied in vitro the effect of MT stabilization using taxol and the Ca2+ accumulation 
inside cultured hippocampal cells. The study showed that pre-treatment of cell cultures with 
10-100 nM of taxol significantly reduced cell death, where 50-70% of the cells survived the 
toxic effect of 50 µM glutamate. In contrast, treatment with 1 µM colchicine (a MT 
destabilizer) resulted in death of more than 70% of the cell population.  The results of these 
studies and others (Kitagawa et al., 1989; Matesic and Lin, 1994; Furukawa and Mattson, 1995; 




immunohistochemical reaction might be an early sign for neuronal degeneration because of 
brain ischemia. 
1.4.2 Reactive oxygen/nitrogen species 
Oxidative damage for mitochondria has been proven to negatively affect the electron transport 
chain (ETC), energy production, lipid peroxidation and DNA damage (Crack and Taylor, 
2005). Furthermore, mitochondrial oxidative stress can modulate the integrity of the 
mitochondrial wall, leading to a decrease of membrane potential and increased Ca2+ 
permeability (Peng and Jou, 2010). This increase in Ca2+ inside the mitochondria leads to a 
reduction in ETC activity and increased production of reactive oxygen species (ROS) (Jendrach 
et al., 2008). Hydroxyl radicals are considered as highly reactive members of the ROS and 
responsible for most oxidative damage such as lipid, protein, and DNA destruction. In addition 
they cause a major inactivation of the ETC (Zhang et al., 1990). Since the brain has a high 
content of lipids, the high generation of ROS due to ischemia will induce more damage.  
In addition to ROS, reactive nitrogen species (RNS) also have a damaging effect on the cellular 
component of the CNS. Nitric oxide (NO) is normally present as a physiological messenger of 
the brain. NO is formed due the activity of NO synthases by the oxidation of L-arginine. NO 
will react with the superoxide O2
.- and the result will be peroxynitrite (ONOO-) (Nanetti et al., 
2007). Peroxynitrite is permeable through a double lipid layer, which will lead to lipid 
peroxidation and also can impair the cellular transduction by inhibition of tyrosine 
phosphorylation (Chen et al., 2013). Furthermore, peroxynitrite will interfere with the cellular 
respiration mechanism by decreasing the ETC as succinate-cytochrome C reductase can be 
highly influenced. It will also affect the activity of cytochrome C oxidase by peroxidation of 
the required lipids for the enzyme activity (Bolaños et al., 1995). Induction of lipid peroxidation 
impairs cell signal transduction, activates inflammatory factors, causes DNA destruction, 
breaks down the BBB, and disrupts cellular respiration, which all lead to neuronal death. These 
are the main mechanisms by which ROS/RNS will exaggerate the ischemic injury of the brain. 
In 2016, Islam et al. conducted an in vitro experiment to assess the role of ROS over the stability 
of MTs. The experiment compared the dynamics of MTs in ROS-free and -rich media. It was 
evident that MTs in ROS-free media have a significantly higher rate of polymerisation/ 
depolymerisation compared to MTs in ROS-rich media (Islam et al., 2016). However, this 




end protected while the plus end is exposed (see also Section 1.6.3.1 on MT polymerisation/ 
depolymerisation). Until now, there is no direct study investigating the role of ROS/ RNS on 
the neuronal or axonal MTs. This area requires further investigation. 
1.4.3 Inflammation 
Inflammation is part of complicated series of biological events in response to cell damage. This 
response can be at a cellular or molecular level. For example, the cellular components include 
microglia, astrocytes, and circulating white blood cells, while the molecular components 
include adhesion molecules such as intracellular adhesion molecules (ICAM) and vascular 
adhesion molecules (VCAM), chemokines such as monocyte chemoattractant protein (MCP) 
and cytokines such as interleukins (IL-1, IL-6, IL-8 and IL-10) and tumour necrosis factor 
alpha (TNF-α) (Nilupul et al., 2006). The inflammatory process usually occurs after the stroke 
due to the course of the brain insult. Some inflammatory cytokines are involved in exacerbating 
the outcome. In regard to the cellular response, leukocytes can be found in response to ischemia 
within 24 h. However, their presence will be masked after 3 days due to the activation of 
microglia (Ahmad and Graham, 2010).   
In the first 24 h after the occurrence of stroke, inflammatory cytokines, especially IL-1, IL-6 
and TNF (Nilupul et al., 2006), erupt to reach 40-60 times their average concentration (Figure 
1.3). This process can last to 7 days after the injury. IL-6 may act as both a neuroprotective and 
neurotoxic agent. A study investigating the plasma concentration of IL-6 found that the higher 
level of IL-6 is correlated to an increased infarct size and less favourable prognosis (Waje-
Andreassen et al., 2005). On the other hand, (Yamada and Hatanaka, 1994) have demonstrated 
the neuroprotective role played by IL-6 in vitro. Table 1.1 summarises the multiple roles for 
different anti/pro-inflammatory molecules and cells. 
Before 2002, it was well established that the activation of proinflammatory molecules, 
especially IL-1, is mediated by caspases. However, the mechanism behind this activation was 
still undiscovered. In 2002, Jürg Tschopp described the protein complexes responsible for this 
activation, known as inflammasomes, and also founded the basic mechanism by which 
inflammasomes work. His work stated that inflammasomes involve caspase-1, caspase-5, the 
protein PYCARD (also known as apoptosis-associated speck-like protein containing a caspase-
activating recruitment domain; ASC), and pyrin rich NOD like receptors (also known as NALP 




(mtDNA) or indirectly by activating proinflammatory cytokines such as IL-1 (Martinon et al., 
2002).  A year later, Tschopp successfully duplicated his results confirming that activation of 
IL-1  requires a complex protein (inflammasome) that is made up from NALPs, ASC, 
caspase-1 and 5 (Tschopp et al., 2003). Tschopp later proved that NLPRs are the key to activate 
caspase-1, which in turn will activate IL-1.   In 2008, Abulafia studied the capability of normal 
or ischemic brain cells to produce inflammasomes and how these molecules can exacerbate the 
ischemic insult. The study found that normal neuronal cells contain NLRP1, ASC, and caspase-
1, and while astrocytes were deficient in ASC and microglia did not contain caspase-1 activity. 
However, in ischemic brain cells, the inflammasome was evident in the three types of cells, 
peaking after 24 hours of the thromboembolic insult (Abulafia et al., 2009). Since then, many 
studies have investigated NLRP1 and 3. These studies found that NLRP 1 and 3 play a major 
role in inflammation after stroke, and that targeting these proteins reduces cellular death in the 
ischemic brain (see (Fann et al., 2013; Ito et al., 2015; Alishahi et al., 2019). 
 
 
Figure 1.3: Diagram showing the time for cellular and molecular responses after ischemic 
stroke (macrophage, ICAM-1: intercellular adhesion molecule-1, IL-6:  interleukin 6, TNF-α: 







Table 1.1: Roles of anti/pro-inflammatory molecules and cells in brain ischemia. From (Jin et 
al., 2013).  
Molecule Anti/Pro  Cells that produce 
the molecule 





protein 1 (MCP-1) 
Pro  Microglia, 
neurons 
Start 3-6 h 
Peak at 12 h 




IL-1 Pro  Microglia, 
macrophages, 
endothelia cells 
Start 2-6 h  





factor  (TNF-) 
Pro  Microglia, 
macrophages, 
endothelial cells 
Start 0.5-6 h 
Peak 12-24 h  




IL-6 Pro  Microglia, 
macrophages, 
endothelial cells 
Start at 12 h  
Peak at 18 h  
Protective  
physiological 
homeostasis of neural 
tissue 
IL-10  Anti Microglia, 
macrophages, T, 
B, astrocytes  
Increase at 10 h 
Peak at 18 h  
Protective 
 




growth factor  
(TGF-) 
Anti  Microglia, 
macrophages 
Increase at 3 h  
Peak at 24 h  
Protective 
 
Decrease inflammation  
Insulin-like growth 
factor 1 (IGF-1) 
Anti  Microglia, 
endothelial 
Increase at 12 h 
Peak at 24 h 
Protective 
 
Neuronal maintenance  
 
In 2013, Misawa et al. investigated the involvement of MTs in the assembly of the 
inflammasome. The study found a reduction in inflammasome production in a macrophage cell 




significant reduction in the production of inflammasomes in cells treated with a MT inhibitor 
and NLPR-3 inducer nigericin. The study assumed that MTs control the localization of NPLR-
3 and ASC, as MTs are the main platform for subcellular transportation. In other words, MTs 
aid in the transportation of mitochondria (the expression sites for ASC) and localisation of 
endoplasmic reticulum (the expression sites for NLPRs) (Misawa et al., 2013). Epothilone D 
would be predicted to stabilize the MT network and enhance the production of inflammasomes, 
facilitating the recovery from stroke.  
1.4.4 Glial cell response to inflammation 
Microglia play a major role in the response to ischemia. Once activated, microglia will produce 
pro-inflammatory molecules that will act as a neurotoxic molecule, such as TNF-α, IL-1, and 
IL-6. Furthermore, they will produce anti-inflammatory molecules that will provide  
neuroprotection, such as IL-10, transforming growth factor-β (TGF-β) and insulin-like growth 
factor-1 (IGF-1) (Zhao et al., 2017). After stroke, studies have shown that microglial activation 
starts as early as 20 minutes in the rat brain and reaches the peak of activation 4-6 days later 
(Morioka et al., 1991). Astrocytes also play a major role in the inflammatory process after 
ischemia. After stroke, astrocytes undergo hyperplastic changes in response to the cytokines 
produced after injury, which is known as astrogliosis (Pekny and Pekna, 2016). A few days 
afterwards, a physical and functional containment of ischemic tissue will be established by 
active astrocytes where the astrocytes will produce inhibitory molecules for axonal 
regeneration such as chondroitin sulfate proteoglycans (CSPGs) (Liu and Chopp, 2016). Active 
astrocytes will also release protective cytokines such as IL-10 and cytokines such as IL-1-α 
and β, and TNF-α that will act as neurotoxic agents and induce the inflammatory process and 
cellular death (Liu and Chopp, 2016).  
Furthermore, astrocytes will participate in the production of NO and ONOO- that will act as 
neurotoxins. This is in addition to the part they play in disturbing the integrity of the BBB, 
which will lead to extravasation of further leukocytes (Nanetti et al., 2007). The produced 
cytokines from injured neuronal cells, microglial cells and astrocytes will also recruit more 
white blood cells to invade the injury site, exacerbating the inflammatory outcome, which may 





1.5 Mechanisms of Recovery 
The improvement timeline for recovery after stroke can be divided into four phases according 
to the time passed since the injury. In human, these phases are the hyperacute phase that lasts 
from 0 to 24 h after injury; the acute phase lasting from 1 to 7 days after the insult; the subacute 
stage lasting from 7 days to 6 months, and the chronic phase that continues from 6 months until 
the improvement is evident (Figure 1.4) (Bernhardt et al., 2017). For stroke survivors with 
neurological impairment, recovery means achieving a status of independency to resume daily 
functions, brought about either by a functional compensation or true recovery (Hylin et al., 
2017). Functional compensation is the ability of the brain to readapt the lost motor function, 
with noticeable weakening of the affected part. This is compared to true recovery that requires 
neuronal regeneration and repair of the synaptic connections (Bernhardt et al., 2017).  
 
Figure 1.4: Schematic diagram showing the timeline of the stages for stroke recovery and the 
progression taking place in each time window in humans. Adapted from (Bernhardt et al., 
2017). 
This functional improvement has underlaying triggering mechanisms, and these mechanisms 
can be conceived into two theories. The first theory is diaschisis, where the intact tissue 
surrounding the stroke will reduce its sensitivity towards the incoming signals, and some of 
these cells will adapt to acquire the function of the dead cells. In other words, it changes the 
brain’s responsiveness to the sensorimotor inputs, and it is mostly evident in rehabilitation 
approaches in an attempt to reduce the neuronal deficits after stroke (Corbett et al., 2017). The 
second theory is that the brain can modulate its function by experiencing significant changes 
in the anatomical and physiological restructuring after stroke (Nudo, 2011). These changes can 
be better explained in terms of brain structural and functional plasticity.  
Brain plasticity is the ability for the brain to change its synaptic connections constantly during 




brain can change, create, or recruit connectional circuits to adapt to a new function or 
compensate for the lost function (Sasmita et al., 2018). Brain plasticity is an attempt of the 
brain to improve the connection networks during learning or after injury (Green and Bavelier, 
2008). This type of plasticity can be investigated at different levels ranging from the neuronal 
level (e.g., remapping the cortex in response to injury) to functional outcomes that compensate 
for a deficit in sensory-motor functions. In a rodent stroke model for example, the regaining of 
sensory motor function can be assessed using behavioural testing such as the retrieval of food 
pellets, or response to sensory stimuli. Specific examples include the adhesive tape test and the 
staircase, grid walk and cylinder tasks that can measure the ability of the animal to reuse the 
stroke-affected limbs (Corbett et al., 2017). At the tissue level, brain plasticity is evident when 
studying biological events such as cellular alterations that involve neuronal, glial and 
vasculature structures. This type of plasticity has been the subject of stroke recovery research 
for decades. It includes investigation of the changes of the cellular components of the neuronal 
network in response to injury and recovery. Such investigations employed different types of 
assessments such as dendritic spine quantification, and axonal regeneration and reconnections 
by using tracing procedures, immunohistochemistry, and genetic markers (Corbett et al., 2017). 
Comprehensively, there are two types of neuronal plasticity that are majorly reviewed: 
structural and functional plasticity.  
1.5.1 Functional plasticity 
Functional recovery depicts the ability of the mature brain to change the current neuronal roles, 
in addition to adapting to handle newer functions. These functional changes mainly occur in 
response to a stimulus such as learning or in response to injury or damage (Freed et al., 1985). 
These functional changes are in a form of long term potentiation (LTP) that occurs due to 
synaptogenesis, and long term depression (LTD) that involves synaptic elimination  
(Bastrikova et al., 2008). In LTP, synaptogenesis is a result of the activity of dendritic 
arborization and dendritic spine development or shrinkage. LTP has two distinct phases: early 
LTP (E-LTP) and late LTP (L-LTP). E-LTP is the sustained stimulation of synaptic 
transmission in a certain brain area. For example, sustained stimulation of the sensory cortex 
will enhance the potentiation of motor cortex neurons, resulting in acquisition of new motor 
skills (Iriki et al., 1989). Ischemic brain injury can induce LTP (iLTP) by specifically endorsing 
neuronal network homeostasis. This involves increasing the excitability of excitatory neurons 




strengthening of excitatory synapses may result in tetanic LTP (tLTP) that reduces the neuronal 
ability to adapt to additional synaptic stimulation (Lenz et al., 2015).    
1.5.2 Structural plasticity 
Structural plasticity is defined as the overall remapping that is initiated by ipsilateral and 
contralateral modifications of neurogenesis, axonal sprouting, dendritic arborization and 
angiogenesis (Andres et al., 2011). After injury in the adult mammalian brain, stroke will 
trigger the migration of neuroblasts from the subventricular zone (SVZ) toward the stroke site. 
After the first week up till the fourth week after stroke, the number of migrating immature 
neuroblasts will dramatically increase, whereupon these cells can be differentiated into mature 
neurons and establish synaptic activity (Ohab et al., 2006; Yamashita et al., 2006). In the 
dentate gyrus, new born neuronal cells start maturation by the differentiation of their dendrites, 
becoming more complicated and embedded in the molecular cell layer (Lledo et al., 2006). 
These cells will express multiple markers such as doublecortin, collapsin response mediator 
protein 4 (CRMP4), calretinin and polysialic acid–neural cell adhesion molecule (PSA–
NCAM). PSA–NCAM is an important neuronal adhesion molecule that is negatively charged, 
which affects the binding capacity of the newly formed neuronal cells and facilitates migration 
(Bonfanti, 2006).  
Axonal sprouting is another form of structural plasticity. In the mature brain, axonal growth 
prevention occurs via three protein classes: myelin-associated proteins (e.g., NogoA, 
glycoproteins, and myelin oligodendrocyte glycoprotein), extracellular matrix proteins (e.g., 
chondroitin sulphate), and development associated growth cone inhibitors (e.g., ephrin, 
semaphorin) (Carmichael, 2006). Targeting these proteins by either genetic deletion or receptor 
blockage has very favourable outcomes regarding axonal regeneration and recovery after stroke 
(Benowitz and Carmichael, 2010; Rust et al., 2019). Axonal sprouting will be initiated in the 
injured cerebral cortex within a few days after stroke. This starts by creating a new axonal 
projection in the areas adjacent to the infarct. These projections may alter the topographical 
mapping of that area (Carmichael and Chesselet, 2002). Two weeks after the initiation of 
sprouting, there is a marked increase of the sprouting axons. However, these axons will not 




1.5.3 Axonal Sprouting and Microtubules  
MTs are polymers that have a hollow cylinder shape with a 25 nm diameter. They are built up 
from tubulin subunits formed by heterodimers of  and  tubulin (Akhmanova and Steinmetz, 
2008; Sloboda, 2015).  and  tubulin units arrange to form protofilaments (PFs) by binding 
to a microtubule organisation centre (MTOC). In neurons, the MTOC consists of two  tubulins 
that bind with two  tubulin complex protein (GCPs), especially GPC 2 and 3. T the result will 
be a  tubulin small complex (TuSC). Several copies will arrange in a ring structure along 
with GPC 4, 5, and 6 to form a  tubulin ring complex (TuRC) (Kollman et al., 2011; Choi 
and Qi, 2014).  
MTs are formed from 13 PFs in neuronal cells, and 9-16 PFs in other cells (the number varies 
between species) (Breuss et al., 2017). They are highly conserved among the evolutionary 
development of eukaryotic cells (Janke, 2014). MTs vary in length, ranging from 1-100 m 
(Odde, 1998) . On average, an axonal cross-section contains 10-100 MTs (Kapitein and 
Hoogenraad, 2015), and these are crosslinked together by MT-associated proteins (MAPs) such 
as MAP-2 and MAP-1 to maintain stability (Subramanian et al., 2010).  
There are two lattice arrangements for tubulin dimers to utilise, an A and a B lattice (Katsuki 
et al., 2012). The lateral bonds with the adjacent dimers determine the lattice. For instance, if 
 dimers bonded laterally with  dimers (i.e., …etc,) it is termed an A lattice (Figure 1.5, 
B1). If the lateral bond is with a homologous dimer (i.e., …etc.,) this is termed a B lattice 
formation (Figure 1.5, B2) (McIntosh et al., 2009; Katsuki et al., 2014; Zhang and Nogales, 
2015). However, in a B-lattice formation the lateral interaction of homologous tubulin units 
will be restricted in one location called a “Seam line” (Figure 1.5A).  In vitro, the assembly of 
PFs starts, and the seam closes up the formation, which usually is in a B-lattice (Hirose et al., 
1995). 
In mammalian cells, MTs start their growth by nucleation from the centrosome in a head to tail 
fashion (Hirose et al., 1995) where the minus end ( dimer) is attached, and the plus end ( 
dimer) points toward the periphery of the cell, i.e. plus end out (Dogterom and Surrey, 2013). 
In neuronal cells, the presence of a centrosome is not mandatory, and the axonal growth fashion 
is seldom arranged with the plus end out (Akhmanova and Hoogenraad, 2015).  In the dendrites 
and spines, it is a mixture between minus end out and a plus end out fashion (Akhmanova and 




instability”, which describes the sudden shortening in MT length or a “catastrophe”, and the 
elongation process named “rescue” (Castle and Odde, 2016). This state of continuous 
elongation and shortening depends on guanosine triphosphate (GTP) binding to the  dimer 
(Conde and Cáceres, 2009) 
 
Figure 1.5:A schematic drawing that illustrates the lattice formation of MTs. A) shows the 
pseudo-helix formation of MTs and the interaction among α, β and γ tubulin. B1) shows the A 
lattice formation illustrated in the lateral formation of heterologous tubulin dimers. B2) depicts 
the B formation with the lateral interaction with homologue tubulin dimers. Adapted from 
(Tovey and Conduit, 2018). 
In the axon, MTs are not in a continuous pattern. This means they are not running continuously 
along the axon length (Nadelhaft, 1974). Two models were proposed to interpret how the 
discontinuous establishment of the MTs can occur. The first model, or polymer transport 
model, states that MTs are formed at the neuronal centrosome, severed, and transported as one 
entity along the axon (Wang and Brown, 2002). The second model, or subunit transport model, 
states that only short MT units are transported along the axon and assembled at the final site 




1.5.3.1 MTs polymerisation/depolymerisation 
When the MT is being assembled, each  /  dimer attaches to a GTP molecule, with the 
difference that the  subunit attaches to the GTP on the non-exchangeable site (N-site), while 
the  subunit attaches to the GTP on the exchangeable site (E-site) (Burns and Farrell, 1996; 
Penazzi et al., 2016).  The  exchangeable site is exposed during assembly, and when the free 
 subunit attaches to the polymerised  dimer, the GTP at the  exchangeable site will 
hydrolyse into guanosine diphosphate (GDP) (Figure 1.6) (Nogales, 2000; Alushin et al., 
2014). Moreover, the GTP cap model states that the ongoing polymerising tubule will keep the 
GTP cap at the  domain, because the loss of this cap will initiate the catastrophe process and 
depolymerisation (Aher and Akhmanova, 2018). For the repair of MTs, there is a considerable 
need for recruiting external dimers rather than using internal modification of the MT dimers 
(Aumeier et al., 2016). When a catastrophe occurs, recruiting of GTP-tubulin to fill up the 
lattice defect may act as a standing base for other external dimers to fill up the deformed lattice. 
This slows down the catastrophe or even repairs the MT (Gardner, 2016).  
 
Figure 1.6: GTP hydrolysis into GDP at the exchange site of β tubulin in the process of the 
polymerisation of MTs. GTP; Guanosine triphosphate, GDP; Guanosine diphosphate, E-site; 
exchangeable site, N-site; non-exchangeable site. Adapted from (Alushin et al., 2014).1.5.3.2 
Microtubules and axonal growth cones 
 
MTs are considered major manipulators of growth cone development, especially in growing 
neurons on a subcellular level. They are required for the outgrowth, elongation and pathfinding 




cytoskeletal components is the major driver for axon elongation and growth cone steering and 
protrusion (Chuckowree and Vickers, 2003). Growth cones are located at the tip of the growing 
axon. They consist of a finger-like projection also referred to as filopodia and a veil-like 
structure known as lamellipodia. In 1986, Goldberg and Burmeister described the 
morphological changes that occur in cultured neurons in response to growth cues. They 
described the process as “a veil like structure that was extended and slowly filled with 
organelles transported in [a] random fluctuant fashion. Afterwards the growth cone gained 
volume and engorged with organelles such as mitochondria. At the end, the growth cone took 
a cylindrical shape of the axon”. In the same publication, Goldberg and Burmeister also defined 
three zones or domains within growth cones. The P domain (peripheral domain) is rich with 
actin; the C domain (central domain) is rich in MTs; and the T zone (transitional zone) separates 
the P and C domain (Goldberg and Burmeister, 1986).  
Axonal extension, steering or even retraction is controlled by the signalling cues that cause 
changes in MT arrangement within the growth cone (Kahn and Baas, 2016). For axonal 
extension, MTs from the C domain invade the P domain, followed by the engorgement of the 
invaded area with transported organelles (Kahn and Baas, 2016). Consolidation then follows, 
causing the growth cone to be extended (Kahn and Baas, 2016). In the process of steering, MTs 
polymerize towards the signalling cues, while the MTs directed on the opposite site of the cues 
will depolymerise allowing the growth cone to move towards the stimulating cue (Kahn and 
Baas, 2016).  
1.6 Microtubules Targeting Drugs 
MT-targeting drugs or agents (MTAs) were first used in cancer therapy. The active chemical 
substances were used to bind to tubulin proteins and thus to inhibit cell multiplication by 
preventing the recruitment of dynamic MTs (Mukhtar et al. 2014). MTAs are classified into 
two subgroups; the first one is the MT destabilising agents, which affect the polymerisation 
process (albeit at high drug concentrations). Examples of MT destabilising agents include vinca 
alkaloids, colchicine and combretastatin. In contrast, the second group is the stabilising agents, 
that stimulate and stabilise cellular MTs. Examples include paclitaxel, docetaxel, and 
epothilones (Jordan and Wilson, 2004; Gabriella et al., 2012). This classification came from 
the ability of the drug to increase or decrease the polymerisation at higher concentrations, by 




the stability will be affected without any interference in the molecular shape or mass of the 
targeted MTs (Mukhtar et al., 2014).  
1.6.1 Paclitaxel/taxol 
Taxol (paclitaxel) is a stabilising agent, discovered in 1967, and the findings about its 
stabilising effect were published in 1979. After clinical trials, taxol was approved for breast, 
ovarian, and lung cancer treatment (Weaver, 2014). The chemical structure of taxol is unique. 
It is structured of a taxane skeleton ring attached to a four membered oxetane ring, and an ester 
chain at C13, which is needed for the activity in mammalian cells (Horwitz, 1992).  Taxol binds 
to  tubulin facing the lumen of the MT, and thus the cytoskeleton of the cell contains a 
considerable number of taxol binding sites (Dı́az et al., 2000). When taxol binds to the inner 
side of  tubulin, it deactivates the GTP hydrolysis on the other side of the binding site. Thus, 
taxol enhances polymerisation and decreases the depolymerisation activity (Baas and Ahmad, 
2013). MT rearrangement in the presence of taxol is a time- and concentration-dependent 
process, such that some taxol-treated cells contain a bundle of induced polymerised MTs 
present in a parallel array (Horwitz et al., 1986).  
Since taxol increases the MT polymerisation process, it will block the process of cell division 
by arresting the cells at S phase (Yeung et al., 1999). The cell will then enter apoptosis (Yeung 
et al., 1999). Due to the inability of taxol to cross the BBB, it will mainly affect the peripheral 
nervous system and will result in a sensory neuropathy (Gornstein and Schwarz, 2014). 
Hypothetically, MTAs will interrupt the active transport mechanism in neuronal cells and will 
result in either axonopathy, ganglionopathy or myelinopathy (Carlson and Ocean, 2011). 
Symptoms of neurotoxicity can be manifest as paraesthesia, numbness and pain in the 
extremities (Lee and Swain, 2006).  
1.6.2 Epothilones 
Epothilones are a type of macrolides, which is a class of drugs consisting of a large macrocyclic 
lactone ring. This was discovered as an antifungal drug derived from the myxobacterium 
Sorangium cellulosum (Clark et al., 2020). Epothilones compete with taxol on the binding site 
and induce the same effect (Bollag et al., 1995; Ganesh et al., 2014). The naturally occurring 
Sorangium cellulosum metabolites give rise to epothilones A and B. These are structurally 
similar with the only difference being that epothilone B (Epo-B, or Epo-906) has a methyl 




isoform (Gabriella et al., 2012). Epothilones C and D are the original precursors for A and B, 
with the same properties and differences at C12 or C13 positions (Gabriella et al., 2012) (Figure 
1.7). As mentioned, epothilones compete with paclitaxel at the binding site and stop calcium-
induced depolymerisation (Goodin et al., 2004). However, epothilones are 2 to 4 times more 
potent than paclitaxel, and epothilone D is more potent that the B isotype. For this reason, and 
the reported toxic effect of epothilone B on the peripheral nerves in vivo and in vitro (Chiorazzi 
et al., 2009), epothilone D is believed to have more pronounced effects on microtubule 
dynamics and function than epothilone B and taxol, resulting in more resilient and flexible 
structures (Forli, 2014).   
 
Figure 1.7: Epothilone structure and comparison among the four classes of epothilone. 
(Adapted from (Huryn and Wipf, 2014)) 
In brain injury models, Xiong et al. (2019) have investigated the effect of epothilone D 
treatment in adult rats after transient global ischemia. The study used two treatment groups (0.5 
mg/kg or a 3 mg/kg dose). The group that received 0.5 mg/kg epothilone D showed a low but 
significant improvement in the number of surviving CA1 cells compared to sham groups. In 
comparison, the group that received 3 mg/kg epothilone D showed a decrease in the number of 
surviving cells compared to the sham group (Xiong et al., 2019). The limitation of this study is 
that the collection of tissues occurred only 2 days after the induction of global ischemia, which 
is the period of abundant ischemic cell death and the peak of the inflammatory process. 
Furthermore, one possible interpretation of the negative effect noted in the 3 mg/kg epothilone 
D group is that over-stabilization of the MTs led to the formation of retraction bulbs and cell 
death. Studies using epothilone D in vitro have shown that high concentrations (10 nM or 
higher) result in a reduction of neuronal cell populations (see (Clark et al., 2020)), that might 
be due to over-stabilization. Ruschel and Bradke (2018) and Sandner et al. (2018) have studied 
the effect of systemic administration of epothilone D in spinal cord contused rats. The treated 
rats exhibited reduced scaring and improved functional recovery compared to controls (Ruschel 




and schizophrenia animal models. Brunden et al. (2010) and Cartelli et al., (2013) demonstrated 
that animals with Parkinsonism treated with epothilone D showed improvement in 
microtubular distribution, integrity, and behavioral outcome (Brunden et al., 2010; Cartelli et 
al., 2013). Zhang et al. (2012) tested the effect of epothilone D on Alzheimer-like pathology in 
mice, where cognitive performance showed a significant improvement (Zhang et al., 2012). In 
a schizophrenia animal model, epothilone D proved to have a significant positive effect on 
synaptic transmission and overall behavioral performance (Andrieux et al., 2006). 
In tauopathies (neurodegenerative disorders such as Alzheimer’s disease that are characterized 
by abnormal tau deposition), epothilone D showed considerable potential by enhancing the 
axonal density and integrity. It also reduced hippocampal neuronal loss during the disease 
without showing any side effects or toxicities (Zhang et al., 2012). Due to their ability to cross 
the BBB, epothilones have the potential to act as neuroprotective agents if administered 
systemically (Jang et al., 2016). However, side-effects of epothilones have been reported, 
including transient neuropathy and diarrhoea. These side-effects were reported to be dose-
dependent and manageable (Donovan and Vahdat, 2008).   
Understanding how MTs are altered after stroke and how manipulating their function promotes 
outgrowth of new connections should facilitate better designs for more appropriate 
pharmaceutical preparations for the treatment of stroke patients. Based on previous studies, it 
is expected that using epothilone D will enhance the behaviour of dendritic MTs and MTs in 
spines in stroke models.  It is also predicted that a higher dose will give a favourable effect in 
the stabilisation of axonal growth cone MTs compared with a lower dose, which will be 
reflected in functional recovery.  
1.7 Summary and Aims of this Thesis 
The functional recovery after stroke is limited. It depends on the ability of the surviving neurons 
to establishing a functional rewiring of the brain after ischemia. This process is controlled by 
the means of successful cellular cytoskeleton stabilisation, and extension. In this research, 
microtubules are being subjected to manipulation that may affect the axonal growth cone 
extension to improve the functional outcome. The hypothesis to be tested in this research is 
that administration of epothilone D will enhance the motor recovery and the axonal sprouting 
after focal stroke in mouse model. Two routes of administration are being tested to study the 




systemic administration include the following: protein binding in the systemic route could 
change the effect of epothilone D on axonal sprouting; epothilone D may be limited in its ability 
to cross the blood-brain barrier, and it could have some cytotoxic effects in peripheral cells. 
Local hydrogel delivery has the potential to circumvent all of these issues. To our knowledge, 
this is a novel study and until the date of submission of this dissertation, there are no published 
materials studying the effect of the microtubule stabiliser drug epothilone D and the functional 
outcome after motor cortex ischemic stroke in mice. This experiment is an extension of the 
Honours research of Delany (2019) (Delany, 2019). Delany studied the effect of local delivery 
of the epothilone D on axonal sprouting only, using Sholl analysis in combination with the 
software Neurolucida 360. In the research in this Masters thesis, two routes of administration 
have been used, and the results were analysed using the computer software Neurolucida 360 
only, along with behavioural analyses for the grid walking and cylinder tasks.  
This project aims to: 
• Assess the efficacy of systemic and local delivery of the microtubule stabilising agent 
epothilone D in vivo on functional recovery, by testing behaviour on the grid and 
cylinder tasks, in a preclinical model of ischemic stroke.  
 
• Assess the efficacy of systemic and local delivery of epothilone D in vivo on axonal 











































All experiments were approved by the University of Otago Animal Ethics Committee, which 
operates according to the Animal Welfare Act 1999. Young adult male C57BL/6J mice (2-3 
months-of-age) (29-35 g) were used and obtained from the University of Otago animal 
breeding facility. Mice were caged in groups of 2-5 animals per cage with access to water and 
feed ad libitum. Animals cages were housed in the University of Otago animal Behavioural 
Phenotyping Unit in a 12 hour light/dark cycle (lights on at 7am) and 21 ± 2 ˚C and 50 ± 2% 
humidity atmosphere. Mice were tested on the light phase. Upon arrival, animals were kept for 
two days without intervention to acclimatize. Animals then randomly sorted into 6 groups of 7 
(n=7). The groups are shown in Table 2.1.  There was no ShamEgel nor ShamSgel groups as 
the gel will be directly injected into the stroke cavity and not the brain parenchyma. 
Table 2.1: Animal grouping (n=7 mice per group). 
Group (n=7) Group treatment 
StrokeEgel Stroke, with 5nM epothilone D in hydrogel 
StrokeSgel Stroke, with 0.9% saline in hydrogel 
StrokeVeh Stroke, with vehicle administered systemically 
ShamVeh Sham, with vehicle administered systemically 
StrokeEsys Stroke, 1.5mg/kg epothilone D administered systemically 




The stroke was induced in the animal’s primary motor cortex using photothrombosis. This 
procedure depends on the photo-activation of a light-sensitive dye, which will react to produce 
singlet oxygen that disrupts the endothelial barriers. The result is that the platelets will 
accumulate and form a thrombus closing the blood vessels (Schroeter et al., 2002; Clarkson et 
al., 2011). Under general anaesthesia using isoflurane (2-2.5%), mice were positioned on a 
stereotaxic apparatus (900 U model, Kopf, USA). All surgeries were performed under aseptic 
technique where a midline surgical site was prepared by clipping hair and sterilized using 30% 
chlorhexidine in 70% ethanol solution using cotton swabs. Using a double sharp end surgical 
scissors, a longitudinal 15 to 20 mm incision was made over the midline of the skull exposing 
underlying tissues that had been separated and the periosteum was peeled off.  Rose Bengal 
(200 µl of a 10 g/L solution) was injected intraperitoneally (IP) and allowed to circulate for 5 




located as close as possible 1.5 mm lateral (left) to bregma, and illuminated the brain through 
an intact skull for 15 min. During this period of illumination, the dye reacted with the light 
causing damage to the blood vessels. The skin was closed using surgical glue (Schroeter et al., 
2002). During the surgery, the mouse was connected to a rectal temperature probe and the 
temperature was maintained at 36.9 ± 0.4°C using a heating pad (Harvard apparatus, 
Massachusetts, USA). After surgery, the mouse was then returned to its home cage and no 
further manipulation was conducted before 5 days after surgery. The timeline from the surgical 
procedure until tissue collection is shown in Figure 2.1. Intraperitoneal injections were given 
one day prior to behavioural testing in week 1 and 2. In week 3, the injection took place 7 days 
after the last treatment. 
 
Figure 2.1 Timeline for the experiment from establishing the pre-behavioural test until tissue 
collection. Week zero represents the stroke surgery and 56 days later tissue collection took 
place. BDA; biotinylated dextran amine, IP; intraperitoneally.  
 
2.3 Drug Delivery 
Two drug delivery routes were used to allow comparing the difference of drug delivery over 
the pharmaceutical properties of epothilone D (MW 491.68, purity 99.93%) (Abcam, UK). The 
hydrogel allows direct targeting of the periinfarct cortex by injecting the gel into the stroke 
cavity. However, epothilone D can also penetrate the BBB and reach the target tissue with a 
less invasive procedure.  
2.3.1 Systemic drug delivery 
A stock solution of epothilone D was made up in ethanol 95% with a concentration of 100 mM. 
This stock solution was then diluted in 0.9% sterile saline to a final concentration of 1.5mg/mL 
(9.14 µL of 100 mM of epothilone D stoke solution in 150 µL saline, final concentration of 
ethanol of 6%). A dose of 1.5 mg/kg (or an equivalent volume of vehicle in control groups) 




concentrations have been chosen based on prior research showing animals injected with 1.5 
mg/kg epothilone B showed fewer retraction bulbs, less dieback and better regeneration in a 
rat model of spinal cord injury (Ruschel et al., 2015). However, the residues of higher doses 
more than 3 mg/kg are more detectable in the brain after a week of injection (Zhang et al., 
2012) . 
2.3.2 Hydrogel 
A hyaluronan/heparin gel was used to deliver the drug (or saline in control groups) directly 
into the stroke cavity for local targeting of the periinfarct cortex. Targeting the periinfarct 
cortex is critical as it is involved in the desired functional recovery (Clarkson et al., 2011). In 
addition, drug delivery into the stroke cavity has the advantage of not interfering with the 
normal brain parenchyma. This hydrogel (Extracell-HP, BioTime, CA) has properties and 
compositions of naturally occurring brain extracellular matrix such as the heparan sulfate 
proteoglycans. As well, the gel does not solidify directly after mixing, which allows the 
injection process to be done with minimal surgical intervention. After 5 days of stroke, animals 
were anesthetized and prepared for surgery as described before. The gel was prepared by 
mixing Heprasil® (thiol-modified hyaluronan plus heparin) and Gelin® (thiol-modified 
gelatin) according to the manufacturer’s instructions in a 1:1 ratio. Afterwards, 3.75 µL of the 
prepared gel will be combined with 3.75 µL of 5 nM epothilone D and 2.5 µL Extralink® 
(polyethylene (glycol) diacrylate). A volume of 7.5 L of gel infused with epothilone D (or 
normal saline as a control) was administered directly into the stroke cavity (1.5 mm lateral 
(left) to the bregma and 0.75 mm deep) using a 30-gauge needle attached to a Hamilton® 
syringe (Hamilton Co., Reno, USA) and micro pump at a rate of 0.5 µL/min. After the 
administration was completed, the needle was left in place for 5 min to allow the infused gel 
to settle. After 5 min, the needle was slowly withdrawn, and the incision was closed using 
surgical glue. Animals were returned to the original cage and were subjected to close 
monitoring for 5 days for postsurgical care.  
2.4 Behavioural Assessment 
Grid walking and a cylinder task were used as behavioural evaluations for post-stroke 
improvement. The tests were done one week before stroke induction surgery to establish a 
baseline for each animal’s performance. Then the animals were tested 1, 2, 4, 6 and 8 weeks 





2.4.1 Grid walking 
This test assesses the ability of a mouse to correctly place the fore limb during natural 
exploration, by measuring the ratio of foot faults to total footsteps completed by the animal. 
The animal was placed on a 32 cm × 20 cm wired grid (12 mm mesh). A mirror placed beneath 
the grid allowed video recording of the mouse movement.  Each mouse was allowed to walk 
for 5 minutes freely. During this time, foot faults and non-foot faults for each forelimb were 
counted. A foot fault was counted when the paw was placed in the gap of the wired mesh, or it 
was correctly placed but slipped due to weight bearing (Barbosa et al., 2015). Then, the ratio 
between foot faults and total footsteps were calculated and converted to a percentage using the 
formula of (number of foot faults / (number of foot faults + non-faults))*100 (Alamri et al., 
2017). Expressing the data as a ratio of total footsteps accounted for differences in the degree 
of locomotion between individual animals and experiments. Faults from the contralateral and 
ipsilateral forelimbs relative to the stroke site were analysed and presented separately, since 
the stroke was expected to primarily affect contralateral limb function. 
2.4.2 Cylinder task 
The animal was freely placed in a vertical cylinder with a dimension of 10 cm in diameter and 
15 cm in length, and recorded for 5 min. During this time, each animal tends to explore its 
surroundings in a vertical fashion. By standing on the rear limbs, the animal was supporting its 
weight on the cylinder wall by its forelimbs, using one or both limbs. A slow-motion video was 
used to calculate the time the animal spent to support its body weight using its right forelimb, 
left forelimb, or both limbs. By calculating the percentage of the time spent using each of the 
forelimbs, the spontaneous forelimb (SFL) asymmetry index can be calculated by the formula 
(% ipsilateral use−% contralateral use) (Santos et al., 2010). 
2.5 Neuroanatomical Tracing 
The neuroanatomical tracer biotinylated dextran amine (BDA, 10,000 molecular weight) is an 
organic compound that is used as a retrograde or anterograde neuronal tracer, with a 
preferential anterograde tracing direction (Reiner et al., 2000). Three hundred nanolitre of 10% 
BDA was injected into the premotor cortex at the coordinates of 1.5 mm lateral (left), 1.75 mm 
rostral to the bregma and 0.7 mm deep into the premotor cortex as motor cortex stroke recovery 
is associated with the plasticity in the premotor cortex (Joy et al., 2019). This was carried out 




of 0.125 µL/min. Anaesthesia and the surgical procedure were as described before in Section 
2.2.   
2.6 Tissue Collection 
Animal euthanasia was completed by deep anaesthesia six days after the tracer injection, using 
a pentobarbital overdose (100 mg/kg). Afterwards, animals were fixed on an absorbent mat 
using tape. Each animal’s responses were checked by pinching of the toe and only when the 
responses were absent, the heart was exposed. Exposing the heart was done by a horizontal 
incision made by scissors across the abdominal wall where the diaphragm was seen. Following 
this, the diaphragm was opened, and a longitudinal incision was made through the length of 
the sternum making an easy access to the heart.  The blood circulation was shortened by 
piercing into the right atrium using a 25 G needle. A trans-cardiac (by the left ventricle) 
perfusion with 4% paraformaldehyde (PFA) (pH 7.4) was carried out using a euthanasia 
apparatus, allowing 30 mL of cold 4% PFA to circulate for about 3 minutes. The brain was 
extracted from the cranium, and the left cerebral cortex was separated from the subcortical 
tissue and flattened between two glass slides with a distance of 1mm separated by steel washers 
to ensure the exact distribution of the flattening (Clarkson et al., 2011). The flattened tissue 
was allowed to rest in 4% PFA for 24 h at 4˚C and then transferred to a solution of 30% sucrose 
overnight before any further manipulation for preventing of water ice crystals and further 
preservation of the cells from swelling (Bahr et al., 1957). 
2.6 Immunohistochemistry and Histology Process 
2.6.1 Sectioning 
Tangential flattened brains were placed on a frozen cryostat stage (Leica, model 1300, 
Biosystem, USA). Afterward the brain and the stage were left to freeze and reach a temperature 
of -21 ˚C before cutting. The stage then was moved toward the cutting blade in a speed not too 
slow to prevent tissue recoiling and not too fast to avoid tissue destruction. Cuts were made 40 
µm in thickness, and each section was placed in a single well in a 24 well plate containing 
cryoprotectant (30% sucrose (w/v), 30% ethylene glycol (v/v), 1% polyvinyl-pyrrolidone (w/v) 
and 50% 0.1 M phosphate buffer (v/v)). Tissues were allowed to settle for at least 24 h before 





Four to five sections 160 µm apart, encompassing the region of BDA injection and spread, 
were selected to be stained for each brain. These sections spanned the different layers of the 
cortex. Sections were washed three times for 10 min each in Tris-buffered saline (TBS) (pH 
7.6). After that, sections were transferred into 0.76% glycine in TBS solution to be washed for 
10 minutes to remove the excess PFA and reduce the non-specific background staining. This 
step was followed by washing in TBS three times for 10 minutes each. To block the endogenous 
peroxidases, sections were washed in a solution made of 8 mL absolute methanol, 11.4 mL 
TBS and 600 µL of 30% hydrogen peroxide (H2O2) for 10 minutes followed by washing three 
times in TBS for 10 minutes each time. After that, sections were incubated in a Vectastain elite 
ABC commercial kit (California, USA) for 90 minutes. The solution was made up of 1:100 
avidin/biotin solution in TBS and 0.3% triton X-100. The avidin component in this solution 
binds to the biotin in BDA. Washing three times for 10 minutes each time was done after this, 
followed by incubation in 3,3’-diaminonenzidine (DAB) solution (1 M DAB in 11.5 mL TBS, 
4 µL of 30% H2O2) up to 15 minutes. The DAB will be converted into brown precipitate by 
the actions of horseradish peroxidase that can be examined under light microscope. After 10 
minutes of the DAB incubation, sections were examined under a light microscope to ensure 
that the DAB colour intensity and distribution are equal and readable. As the last step, sections 
were washed for three times in TBS for ten minutes each run. Sections were mounted to glass 
slides and left to dry. 
After drying, slides were dehydrated in ascending ethanol concentrations for 1 minute starting 
from 50% concentration then 70% and ending in absolute concentration. Slides were then 
transferred into xylene for another 1 minute. Slides then were taken out of the xylene and left 
to drain out before applying dibutylphthalate polystyrene xylene (DPX) (an anhydrous 
medium) and cover slipping. Slides were then left overnight for the DPX to dry. All of the 
mentioned steps were performed at room temperature and a fume hood was used when needed. 
2.7 Microscopy 
Sections were examined and imaged at 20x objective lens * 10x ocular lens with a bright field 
microscope (Olympus, Japan) and the aid of Stereo-investigator software (MBF Bioscience, 
USA). The whole stained brain section was imaged and used for automatic tracing of the axons 
using Neurolucida 360 (MBF Bioscience, USA). Imaging was done by determining the 




as the area of interest to be used later for fine adjustment. The contoured section then was 
automatically divided into multiple adjustment sections (250-350 section). Twenty random 
sections then were used for fine adjustment and to obtain clear image. 
2.8 Image Analysis 
All image analysis was carried out using Neurolucida 360 (NL360). For every animal in each 
treatment group, 4-5 sections were obtained, imaged and analysed. This computer-aided 
software allowed the automatic tracing for stained axons, however, manual tracing for some 
axons that were clearly mistraced by Neurolucida was carried out as well. Including the 
manually traced axons would not interfere with any further analysis. Each axon is represented 
by a line. The line itself is divided into points and each point is considered as a data point 
embodied in x,y coordinates. Data points for each group was entered into an Excel sheet and 
used to generate a heatmap representative for data pooled from all animals in the treatment 
group. For intra-group comparison, heat maps were overlapped, and the statistical difference 
was shown. The heat maps were also used to generate a polar description for sprouting direction 
and amplitude. The statistical analysis, described in section 2,9 below, takes into account not 
only the magnitude of axonal sprouting (i.e the number of data points), but also the 
directionality of sprouting from the BDA injection site. 
2.9 Statistical Analysis 
Behavioural data were analysed using two-way ANOVA followed by Holm-Šídák's test for 
multiple comparisons. Time after stroke and treatment group were the ANOVA factors. At key 
times after stroke, the treatment effects were also analysed and presented by one-way ANOVA. 
This was also followed by Holm-Šídák's post-hoc test for multiple comparison. The analysis 
for this data was done by using GraphPad Prism (v 8, GraphPad Software, California, USA). 
Data from image tracing were analysed using Hotelling’s t2 test (Overman et al., 2012). 
Calculations for Hotelling’s t2 test was performed by a previously written code on R software 
(v 2.15.0, R foundation for statistical analysis). The significance level was considered 






















































3.1 Systemic (but not Local) Epothilone D Promotes Functionality in the 
Affected Motor Cortex 
3.1.1 Systemic epothilone D treatment effects on grid walking 
In the grid walking task, the percentage of foot faults across all time points in the forelimb 
contralateral to the stroke injury side are shown in Figure 3.1 for systemic treatments. There 
was no effect of systemically-delivered epothilone D on percentage of foot faults in animals 
that received only sham surgery (F (1, 12) = 1.55, p=0.24) (Figure 3.1a). On the basis of this, the 
shamEsys group was selected as the non-stroke control for comparison with stroke groups. In 
the systemically-treated groups, the percentage of contralateral foot faults differed significantly 
over time (two-way ANOVA, F (2.43, 43.79) = 28.99, p<0.001) and between treatment groups 
(two-way ANOVA, F (2, 18) = 47.17, p<0.001). There was also a significant treatment group x 
time interaction (F (10, 90) = 6.81, p<0.001), indicating that the changes in foot faults over time 
were not equivalent across the three groups. Overall, the percentage of contralateral foot-faults 
dramatically increased on the first week after the insult in both stroke groups (p<0.001 
compared to pre-op levels for these groups, and p<0.001 compared to the shamEsys group in 
week 1), while the shamVeh group showed no change in the percentage of the contralateral 
foot faults across time at any stage of the experiment (Figure 3.1b). The percentage of 
contralateral foot-faults declined in the strokeEsys group from week 4 onwards (p<0.01 
compared to week 1 values in weeks 4 and 6; p<0.001 compared to week 1 values in week 8). 
In contrast, there was no or minimal decline in the percentage of foot-faults in the strokeVeh 
group (p=0.05 in week 4 compared to week 1; otherwise not significant). The net effect of this 
was a progressive improvement in grid walk performance in the contralateral limbs of 
strokeEsys mice compared to strokeVeh mice (p<0.05 at weeks 4 and 6; p<0.01 at week 8). By 
week 6, foot fault percentage in strokeEsys mice was not significantly different than in 
shamEsys mice (p=0.09), however at week 8 these groups were again significantly different 
(p<0.01). Therefore, a full recovery from stroke in response to systemic epothilone D was not 
consistently achieved in the grid walk test of contralateral limb performance by the end of the 
experiment. Figure 3.1c and d show a more detailed analysis in the foot faults percentage 
among groups at weeks 1 and 8 after stroke, respectively. One-way ANOVA followed by 
Holm-Šídák's test for multiple comparison was used. In week 1 (Figure 3.1c) there was a highly 
significant increase in foot faults in both stroke groups compared to the shamEsys group 
(p<0.001) as well as a difference between the strokeEsys and strokeVeh groups (p<0.001). In 




strokeVeh); however, there was still a statistically significant difference between strokeEsys 
and shamEsys groups at this time (p=0.008). 
















































(a) Contralateral foot faults across all
weeks among shamVeh and shamEsys
(c) Contralateral foot faults analysed at week















































(b) Contralateral foot faults across all weeks
among strokeEsys, shamEsys and strokeVeh
(d) Contralateral foot faults analysed at week
8 among strokeEsys, shamEsys and
strokeVeh
 
Figure 3.1: Behavioural recovery in the contralateral (right) forelimb grid walking task for 
systemically-treated mice. (a) No effect of epothilone D in sham surgery mice. (b) An increase 
in foot-faults compared to the pre-op base line and compared to sham mice at 1 week after 
stroke was seen in strokeVeh and strokeEsys mice, and a regain in function from week 4 
onwards was evident in mice treated with 1.5 mg/kg i.p. epothilone D compared to stroke, 
vehicle-treated mice. (c) Week 1 systemic treatment group one-way analysis of variance 
results. (d) Week 8 systemic treatment group one-way analysis of variance results.  Data are 
presented as mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001 (strokeEsys vs. shamEsys); $ 
p<0.05, $$ p<0.01, $$$ p<0.001 (strokeEsys vs. strokeVeh); ### p<0.001 (shamEsys vs. 
strokeVeh; this comparison not shown in panel b for clarity). See main text for statistical 






In contrast to the contralateral forelimb, the ipsilateral forelimb remained largely unaffected by 
the stroke and treatment as is shown in Figure 3.2. Two-way ANOVA revealed no effect of 
systemically-delivered epothilone D on percentage of foot faults in animals that received only 
sham surgery animals (F (1, 12) = 0.24, p=0.63). However, there was a significant effect of time 
(F (2.3, 27.65) = 10.07, p=0.0003), with no significant time x treatment group interaction (Figure 
3.2a). Pre-op ipsilateral foot faults were significantly lower than those at all other time points 
for both sham surgery groups (p<0.05), except for pre-op vs. 1 week in shamVeh mice 
(p=0.13). Ipsilateral foot faults did not vary significantly across any other time points. Since 
both the groups had received sham surgery only, the change in ipsilateral footfalls compared 
to pre-op was unexpected, potential reasons have been discussed in Section 4.2.2. In the three 
systemically-treated groups (with the shamEsys group used as the non-stroke control for 
comparison with stroke groups), the percentage of foot faults also differed significantly over 
time (two-way ANOVA, F (5, 90) = 19.85, p<0.001), with post-hoc test again showing less pre-
op foot faults compared to all later time points in all groups (p<0.05) (Figure 3.2b). In this case 
there was also a significant treatment effect (F (2, 18) = 6.77, p<0.006), but there was no 
significant time x treatment group interaction and post-hoc testing revealed no treatment group 
effects except for one significant difference between shamEsys vs. strokeVeh groups at 6 
weeks (p=0.002). In more detailed analysis using one-way ANOVA for week 1 and 8 among 
the systemically treated groups, it was shown that there were no significant changes among the 

















































(c) Ipsilateral foot faults analysed at week 1






























(d) Ipsilateral foot faults analysed at week 8
among strokeEsys, shamEsys and strokeVeh














(b) Ipsilateral foot faults across all weeks among
strokeEsys, shamEsys, and strokeVeh
 
Figure 3.2: Grid walking task results related to the ipsilateral (left) forelimb showing no 
significant differences in foot fault percentage across systemically-treated groups, suggesting 
there is no relationship between the injury and ipsilateral limb. a) No effect of epothilone D in 
sham surgery mice. (b) An increase in foot-faults compared to the pre-op base line was 
observed in all groups at all subsequent times, but the treatment groups did not differ from each 
other at specific time points (shamEsys vs. strokeVeh comparisons not shown in panel b for 
clarity). (c) Week 1 systemic treatment group one-way analysis of variance results. (d) Week 
8 systemic treatment group one-way analysis of variance results. Data presented as mean  








3.1.2 Local (hydrogel) epothilone D treatment effects on grid walking 
The percentage of foot faults across all time points in the forelimb contralateral to the stroke 
injury side are shown in Figure 3.3. Since sham surgery animals were not able to be treated 
with hydrogel into a stroke cavity, the shamEsys group was used as a non-stroke control for 
comparison with two hydrogel-treated stroke groups. In these three groups, the percentage of 
foot faults differed significantly over time (two-way ANOVA, F (4.00, 72.08) = 33.77, p<0.001) 
and between treatment groups (two-way ANOVA, F (2, 18) = 40.10, p<0.001). There was also a 
significant treatment group x time interaction (F (10, 90) = 5.76, p<0.001), indicating that the 
changes in foot faults over time were not equivalent across the three groups. As was the case 
for systemically-treated mice, the percentage of contralateral foot-faults dramatically increased 
on the first week after the insult in both stroke groups (p=0.01 for strokeEgel and p<0.001 for 
strokeSgel compared to pre-op levels for these groups, and p<0.001 compared to the shamEsys 
group in week 1) (Figure 3.3a). The percentage of contralateral foot-faults did not decline 
significantly compared to week 1 values in either the strokeEgel of strokeSgel groups. 
StrokeSgel contralateral foot faults remained significantly higher (p<0.01) than those for 
shamEsys mice throughout the experiment, however at weeks 6 the foot faults for strokeEgel 
mice were not significantly different from those in shamEsys mice (p=0.053). At week 8 these 
groups were again significantly different (p=0.02). At no time was there a difference between 
the strokeEgel and strokeSgel groups. Therefore, a clear recovery from stroke in response to 
local epothilone D was not achieved in the grid walk test by the end of the experiment. Figure 
3.3b and c show a more detailed analysis in the foot faults percentage among groups at weeks 
1 and 8 after stroke, respectively. One-way ANOVA followed by Holm-Šídák's test for 
multiple comparison was used. In week 1 (Figure 3.3b) there was a highly significant increase 
in foot faults in both stroke groups compared to the shamEsys group (p<0.001). This difference 
persisted at week 8 (Figure 3.3c) for the strokeSgel group (p<0.001) and also for the strokeEgel 







(a) Contralateral foot faults across all weeks among strokeEgel, strokeSgel, and shamEsys
(b) Contralateral foot faults analysed at week
1 among strokeEgel, strokeSgel, and
shamEsys












































































(c) Contralateral foot faults analysed at week
8 among strokeEgel, strokeSgel, and
shamEsys
 
Figure 3.3: Behavioural recovery in the contralateral (right) forelimb grid walking task for 
locally-treated mice. (a) An increase in foot-faults compared to the pre-op base line and 
compared to sham mice at 1 week after stroke was seen in strokeSgel and strokeEgel mice, and 
a slight regain in function from week 6 was evident in mice treated with 5 nM epothilone D 
compared to sham mice. (b) Week 1 local treatment group one-way analysis of variance results. 
(c) Week 8 local treatment group one-way analysis of variance results.  Data are presented as 
mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001 (strokeEgel vs. shamEsys); ### p<0.001 
(shamEsys vs. strokeSgel; this comparison not shown in panel a for clarity). See main text for 
statistical comparisons across time, and for the rationale for inclusion of the shamEsys group 







In contrast to the contralateral forelimb, the ipsilateral forelimb remained largely unaffected by 
the stroke, as shown in Figure 3.4. As with the ipsilateral forelimb data from systemically-
treated mice, two-way ANOVA on the locally-treated groups (with the shamEsys group used 
as the non-stroke control for comparison with stroke groups) revealed a significant effect of 
time (F (2.77, 49.81) = 22.63, p<0.0001), with post-hoc tests again showing less pre-op foot faults 
compared to all later time points in all groups (p<0.05) and, in the strokeSgel group, a further 
significant increase in foot faults at weeks 4 and 6 compared to week 2 (p=0.03). There was 
also a significant treatment effect (F (2, 18) = 7.45, p=0.004) and a time x treatment interaction 
(F (10, 90) = 2.45, p=0.01), with post-hoc testing showing less foot faults in the shamEsys group 
compared to strokeEgel and strokeSgel animals at weeks 4 and 6 (p<0.05) (Figure 3.4a). In a 
more detailed analysis using one-way ANOVA for week 1 and 8 among the locally treated 
groups, it was shown that there were no significant changes among the treatment groups (Figure 



















(a) Ipsilateral foot faults across all weeks among
































(b) Ipsilateral foot faults analysed at week 1






























(c) Ipsilateral foot faults analysed at week 8
among strokeEgel, strokeSgel and shamEsys
 
Figure 3.4: Grid walking task results related to the ipsilateral (left) forelimb showing no 
significant differences in foot fault percentage across locally-treated groups, suggesting there 
is no relationship between the injury and ipsilateral limb. a) An increase in foot-faults compared 
to the pre-op base line was observed in all groups at all subsequent times. Sham surgery animals 
exhibited less ipsilateral foot faults compared to both stroke groups at weeks 4 and 6 (shamEsys 
vs. strokeVeh comparisons not shown in panel a for clarity). (b) Week 1 local treatment group 
one-way analysis of variance results. (c) Week 8 systemic treatment group one-way analysis 
of variance results. *p<0.05 (strokeEgel vs. shamEsys). Data presented as mean  SEM. See 
main text for statistical comparisons across time. 
3.1.3 Systemic epothilone D treatment effects in the cylinder test 
In the cylinder test, the asymmetry index across all time points is shown in Figure 3.5 for 
systemic treatments. Data were analysed using mixed effect analysis due to missing values for 
animals which failed to produce the threshold number of movements (in this case 5, as used in 
Clarkson’s laboratory). There was no effect of systemically-delivered epothilone D on the 




3.5a). On the basis of this, the shamEsys group was selected as the non-stroke control for 
comparison with stroke groups. In the systemically-treated groups, the asymmetry index 
remained unchanged over time (mixed effect analysis, F (5, 62) = 2.109, p=0.08). Still, there was 
a significant difference between treatment groups (two-way ANOVA, F (2, 18) = 12.36, p<0.001) 
and treatment group x time interaction (F (10, 62) = 2.26, p=0.03), indicating that the changes in 
the asymmetry index over time were not equivalent across the three groups. In post-hoc tests, 
only the strokeVeh group showed an increase in the asymmetry index over time compared to 
the pre-op values (at weeks 2 and 6, p<0.05). In strokeVeh animals, the asymmetry index was 
elevated significantly after one week of stroke in comparison to the shamEsys group and 
remained elevated through to week 6 (p<0.01), whereas in strokeEsys animals the asymmetry 
index was only elevated in comparison to the shamEsys group at week 1 (p=0.001). The 
asymmetry index for strokeEsys mice did not improve to the extent of differing significantly 
from strokeVeh animals at any time point (Figure 3.5b). Figure 3.5c and d show a more detailed 
analysis in the asymmetry index among groups at weeks 1 and 8 after stroke, respectively. One-
way ANOVA followed by Holm-Šídák's test for multiple comparison was used. There was an 
evident significant change among both systemically treated stroke groups (strokeEsys, 
strokeVeh) compared to shamEsys in the first week (p<0.01). However, these changes had 
disappeared at week 8. This suggests that the cylinder test was able to differentiate between 
stroke and sham groups for a short time but was limited in its ability to distinguish between the 












































































































(a) Asymmetry index across all weeks
among shamVeh and shamEsys
(b) Asymmetry index across all weeks among
strokeEsys, shamEsys, and strokeVeh
(c) Asymmetry index analysed at week 1
among strokeEsys, shamEsys and strokeVeh
(c) Asymmetry index analysed at week 8
among strokeEsys, shamEsys and strokeVeh
 
 
Figure 3.5: Asymmetry index for systemically-treated mice. (a) No effect of epothilone D in 
sham surgery mice. (b) An increase in asymmetry index compared to sham mice at 1 week 
after stroke was seen in strokeVeh and strokeEsys mice (shamEsys vs. strokeVeh comparisons, 
which were significantly different through to week 6, are not shown in panel b for clarity).  (c) 
Week 1 systemic treatment group one-way analysis of variance results. (d) Week 8 systemic 
treatment group one-way analysis of variance results.  Data are presented as mean ± SEM. ** 
p<0.01, (strokeEsys vs. shamEsys); ## p<0.01 (shamEsys vs. strokeVeh). See main text for 









3.1.4 Local (hydrogel) epothilone D treatment effects in the cylinder test 
The asymmetry index across all time points is shown in Figure 3.6 for local treatments. Since 
sham surgery animals were not able to be treated with hydrogel into a stroke cavity, the 
shamEsys group was used as a non-stroke control for comparison with two hydrogel-treated 
stroke groups. As was the case with systemically-treated groups, the asymmetry index did not 
differ significantly over time (mixed effect analysis, F (5, 79) = 1.24, p=0.30). There was a 
significant effect of treatment group (F (2, 79) = 11.02, p<0.001) and a significant treatment group 
x time interaction (F (10, 79) = 2.61, p=0.009), indicating that the changes in forelimb asymmetry 
over time were not equivalent across the three groups. Unlike systemically-treated mice, the 
forelimb asymmetry dramatically increased after the insult only in the strokeEgel stroke group 
(across time, significant compared to pre-op levels at weeks 2 and 4, p<0.01; across groups, 
significant compared to shamEsys at weeks 1-4, p<0.01). Unexpectedly, strokeEgel asymmetry 
index values were higher than strokeSgel values at weeks 2 and 4 (p<0.05) (Figure 3.6a). Figure 
3.6b and c show a more detailed analysis in the asymmetry index among groups at weeks 1 and 
8 after stroke, respectively. One-way ANOVA followed by Holm-Šídák's test for multiple 
comparison was used. The asymmetry index was significantly elevated at the 1-week time point 
in strokeEgel mice relative to both shamEsys (p=0.001) and strokeSgel (p=0.02) mice. The 
difference had disappeared at week 8. This unexpected increase in asymmetry index in the 
strokeEgel group, and the absence of any effect of the stroke in the strokeSgel group, can be 
interpreted as the cylinder test failing to distinguish between groups for a long time, in addition 
to the small stroke size caused by the photothrombosis not inducing a very pronounced 
behavioural outcome for this analysis. The cylinder test can show better results with a larger 





























































































(a) Asymmetry index across all weeks among
strokeEgel, strokeSgel, and shamEsys
(b) Asymmetry index analysed at week 1
among strokeEgel, strokeSgel and shamEsys
(c) Asymmetry index analysed at week 8
among strokeEgel, strokeSgel and shamEsys
 
Figure 3.6: Asymmetry index for locally-treated mice. (a) An increase in the asymmetry index 
compared to the pre-op base line and compared to sham mice at 1-4 weeks after stroke was 
seen in mice treated with 5nM infused epothilone D in gel, and also compared to stroke, saline-
treated mice at weeks 2 and 4. (b) Week 1 systemic treatment group one-way ANOVA results. 
(c) Week 8 systemic treatment group one-way ANOVA results.  Data are presented as mean ± 
SEM. ** p<0.01, *** p<0.0001 (strokeEgel vs. shamEsys); $ p<0.05, $$ p<0.01 (strokeEgel 





3.2 Epothilone D Promotes Axonal Sprouting 
Axonal sprouting starts taking a place as early as three weeks after stroke (Carmichael et al., 
2017). This can be detected using anatomical mapping of the adjacent circuits. In this thesis 
NL360 was used to trace BDA-labelled processes longer than 5µm in length (Figure 3.7). Each 
traced axon was represented by a line and each point in that line was considered as a datapoint. 
Using a specified heatmap generator, data points were embodied in an x,y chart using 
coordinates obtained from NL360. Each heatmap is a scheme of 7 animals (per group). Polar 
configuration was also shown depicting BDA-traced neuron projections and distribution of the 
projections. This represents the newly formed archetypes from the motor and premotor 
cortexes.  
 
Figure 3.7:Image of mouse brain section showing BDA axonal labelling and the region of 
interest for this research. (Adapted from Delany, 2019) 
The figure below (Figure 3.8) illustrates the region of interest on a normal presentation of the 
brain surface and the same regions represented on a tangential section of the brain. The stroke 
took place in the motor cortex (light blue) and the BDA injection was placed in a region 1.75 
mm rostral of the stroke in the premotor cortex (dark blue). Each map also depicts the 





Figure 3.8: (a) Different regions on normal presentation of the brain. Stroke was induced in the 
motor cortex followed by BDA injection the premotor cortex (b) The same regions shown in 
(a) on a tangential section of the brain. (Modified from Overman et.al, 2012). 
 
3.2.1 The effect of systemic administration of epothilone D on axonal sprouting  
We conducted pairwise comparisons of the various groups to demonstrate the effect of 
epothilone D in regards of axonal sprouting after stroke. Heatmaps were generated for each 
group (shamEsys, shamVeh, strokeEsys, and strokeVeh) (Figure 3.8). For each comparison, 
polygons are shown representing the 70th percentile of the distance of the labelled axonal 
growth projection from the injection site. Each section of the graph was also generated using 
the same customised software. The heat maps depict the extent of axonal sprouting as marked 
by BDA tracing, but not the density of staining. The statistical comparison takes into account 
not only the magnitude of axonal sprouting (i.e., the number of data points), but also the 
directionality of sprouting from the BDA injection site (depicted as polar vectors in the images 





Figure 3.9: Generated heatmap for systemically administered epothilone D. a) shamEsys 
axonal sprouting heatmap. b) shamVeh axonal sprouting heatmap. c) strokeEsys axonal 
sprouting heatmap. d) strokeVeh axonal sprouting heatmap. Numbers are expressed in µm. 
BDA injection site represented by the hollow centre. Stroke site is represented with the grey 
circle in c and d. 
 
Table 3.1: P value of the magnitude and directionality of axonal sprouting between sham 
groups (shamEsys vs shamVeh). 
Group P value 
shamEsys vs shamVeh 0.052 
Statistical analysis was done by a previously written R code using Hotelling’s t2 test. There 




that received only sham surgery animals (p=0.052) (Table 3.1 and Figure 3.9).  However, 
systemic administration of epothilone D in sham animals may have caused a non-significant 
trend in the quantity and directionality of the traced axons. Because the difference was not 
statistically significant, and because of some poor quality sections present in the shamVeh 
group, the shamEsys group was selected as the non-stroke control for comparison with stroke 





Figure 3.10: Comparison between shamEsys and shamVeh groups. a) Overlapped heatmap for 
both groups. Systemic administration of epothilone D in animals received sham surgery did 
not show any significant change in axonal sprouting. p=0.052. b) Polar representation of the 
normal distribution of data points in graph segments. BDA injection site represented by the 






In systemic treatment of epothilone D in stroke animals (strokeEsys), epothilone D induced 
more pronounced axonal sprouting represented by the quantity and the direction of the traced 
axons in comparison with strokeVeh (p=0.012) (Table 3.2 and Figure 3.10). Nevertheless, 
systemic epothilone D still did not induce sufficient axonal sprouting to eliminate the statistical 
differences between strokeEsys and shamEsys (shamEsys vs strokeEsys p=0.001) (Figure 
3.11).  
Table 3.2: P value of the magnitude and directionality of axonal sprouting among systemically 
treated groups. 
Group P value 
shamEsys vs strokeEsys 0.001 
shamEsys vs strokeVeh 0.17 







Figure 3.11: Comparison between strokeEsys and strokeVeh groups. a) Overlapped heatmap 
for both groups. Systemic administration of epothilone D in animals received stroke surgery 
showed a significant change in axonal sprouting. p=0.012. b) Polar representation of the normal 
distribution of data points in graph segments. BDA injection site represented by the hollow 







Figure 3.12: Comparison between shamEsys s and strokeEsys groups. a) Overlapped heatmap 
for both groups, p=0.001. b) Polar representation of the normal distribution of data points in 
graph segments. BDA injection site represented by the hollow centre. Stroke site is represented 




3.2.2 Local treatment of epothilone D did not promote axonal sprouting 
The axonal sprouting for shamEsys and shamVeh is shown in Figure 3.9. Since sham surgery 
animals were not able to be treated with hydrogel into a stroke cavity, the shamEsys group was 
used as a non-stroke control for comparison with two hydrogel-treated stroke groups. Heatmaps 
were generated for each group (shamEsys, strokeEsys, and strokeVeh) (Figure 3.12). For each 
comparison, polygons representing the 70th percentile of the axonal growth projection 
expressing the distance of labelled axons from the injection site in each section of the graph 
were also generated using the same customised software. 
 
Figure 3.13: Generated heatmap for locally administered epothilone D. a) strokeEgel axonal 
sprouting heatmap. b) strokeSgel axonal sprouting heatmap. BDA injection site represented by 
the hollow centre. Stroke site is represented with the grey circle. Numbers shown are in µm. 
 
In the comparison of shamEsys and strokeEgel, local treatment with 5 nM epothilone D infused 
gel did not prompt axonal growth, and the statistical difference between these two groups 
(p=0.007) indicates that local treatment with epothilone D didn’t induce enough additional 
sprouting to be reflected in the heat map data (Table 3.3 and figure 3.13). This difference backs 
up the results obtained of behavioural testing (Figure 3.3), where only minimal effects of local 
epothilone D were observed. In support of this conclusion, comparison of the two stroke groups 
treated with gel (epothilone D or saline) showed there was no significant effect of local 






Table 3.3: P value of the magnitude and directionality of axonal sprouting among locally 
treated groups. 
Group P value 
shamEsys vs strokeEgel   0.007 
shamEsys vs strokeSgel 0.038 






Figure 3.14: Comparison between shamEsys and strokeEgel groups. a) Overlapped heatmap 
for both groups, p=0.007. b) Polar representation of the normal distribution of data points in 
graph segments. BDA injection site represented by the hollow centre. Stroke site is represented 





Figure 3.15: Comparison between strokeEgel and strokeSgel groups. a) Overlapped heatmap 
for both groups. p=0.211. b) Polar representation of the normal distribution of data points in 






















































4.1 Aims and Key Findings 
Based on previous literature reporting the beneficial effects of treatment with epothilone D in 
vivo in Alzheimer’s disease, Parkinson’s disease, schizophrenia and after spinal cord contusion 
(Andrieux et al., 2006; Brunden et al., 2010; Zhang et al., 2012; Cartelli et al., 2013; Ruschel 
and Bradke, 2018; Sandner et al., 2018) (see also Chapter 1), the experiments in this thesis 
tested the effect of  epothilone D on neocortical reorganization after focal stroke. The use of 
systemic epothilone D to target MTs, as an attempt to reduce cortical connection abnormalities 
and improve motor function, was found to be beneficial.  
The positive effect for systemic epothilone D on promoting functional recovery was best 
depicted in the analysis of grid walking. This result was successfully duplicated in the outcome 
of axonal sprouting. Stroke animals that received 1.5 mg/Kg epothilone D systemically showed 
better axonal sprouting with a statistically significant change in comparison to those which had 
not received the treatment. In addition, the consistency of those results strongly supports the 
hypothesis of this project, demonstrating the positive effect of systemic epothilone D on the 
functional and axonal sprouting outcomes. In contrast, local delivery of the drug failed to 
produce any measurable effect on the same measured outcomes. These findings are discussed 
in more detail in Sections 4.3 and 4.4. Prior to this, methodological considerations are discussed 
in the next section. 
4.2 Methodological Considerations 
4.2.1 The advantages of epothilones 
Epothilones are a novel drug that have shown great potential for malignancy treatment. The 
mechanism of action for this class of drugs is to increase the stabilisation of the MTs of the 
cytoskeleton, leading to a reduction in a cell’s ability to divide. This action is like that of 
paclitaxel. However, epothilones prevail over paclitaxel in many aspects such as the simplicity 
of the molecular structure of the compound, making it easier to be completely formed 
synthetically. Another aspect of epothilones’ advantage is its higher solubility in water. Most 
importantly to the experiments of this thesis is the ability of epothilones to cross the BBB to 






4.2.2 Behavioural analyses 
For the grid walking test, animals were tested prior to the stroke to establish a baseline for the 
comparison. After one week of stroke, the contralateral foot-faults for all stroke groups had 
elevated simultaneously (Fig. 3.1b). This proved the effect of stroke on the motor performance 
of the animals. Later after treatment, animals in the StrokeEsys group started to show a 
reduction in the foot-fault percentage in comparison to stroke animals which received no 
treatment such as the StrokeVeh group (Fig. 3.1b). This difference persisted over the latter 
experimental period (Fig. 3.1b). A significant difference started to be evident on the level of 
contralateral fault-foots in week 1 and continued until the end of the treatment at week 8 (Fig. 
3.1d). In the ipsilateral limb tested on the grid walk, the increase of the foot faults for the 
unaffected limbs (Fig. 3.2b) is related to the dependency of the animal on the unaffected (left) 
limb to explore and bear weight causing more slips of the ipsilateral limbs (Chao et al., 2012). 
In ipsilateral foot faults in sham animals, two-way ANOVA had shown a significant effect of 
time over the number of foot faults. It is possible that animal habituation over time led to a 
decrease the total number of footsteps due to the reduction in the animal’s interest to explore 
the environment (Chao et al., 2012) (see Appendix A in Section 6.1). This reduction of the total 
number of footsteps may have led to the increase of faults and increased the percentage over 
time. 
The lack of significant changes in the cylinder task in the experiments of this thesis (Fig. 3.6) 
could be due to many factors. In the current study, a therapeutic agent is being tested to measure 
the neuroplasticity and re-organisation after focal ischemia in mice, which also requires the 
presence of reliable behavioural tests. According to the literature, most of the behavioural tests 
are designed to test the effect of therapeutic agents in rats and higher mammals and more 
adjustments are essential to validate behavioural testing in mice (Alaverdashvili and Whishaw, 
2013; Balkaya et al., 2018). Additionally, mice exhibit a great spontaneous recovery after an 
ischemic insult (Balkaya et al., 2018). More specifically, despite being used extensively in rats, 
the cylinder task is reported to have a low sensitivity for a chemically-induced ischemic insult 
in the mouse brain (Tennant and Jones, 2009; Balkaya et al., 2012). In addition, the cylinder 
task in mice can be used to distinguish between sham and stroke animals, however, the same 
test fails in distinguishing between treatment groups (Li et al., 2004). In this experiment, the 
cylinder task showed inconsistent results about the asymmetric index (Fig. 3.6a). It was clear 
that stroke animal treated with local administration of epothilone was affected by the stroke 




showed a minimal change in the performance in the same task. Still, the test succeeded in 
distinguishing between stroke and sham animals (Fig. 3.b) yet failed in distinguishing between 
stroke groups (Fig. 3.6c). This variation in results is consistent with the reasons mentioned 
above in this section, such as stroke size and model, and the subject animals that have been 
tested. 
In conclusion, in this study, the grid walking was better to detect differences among stroke and 
sham groups, and between stroke groups, and was more reliable than the cylinder test. 
4.2.3 Induction of the focal stroke  
The photothrombosis model of stroke seeks to induce ischemic damage to a specified cortical 
region. It causes stroke by the production of single oxygen molecules as a result of light 
sensitive dye activation by a certain wavelength of light. The singlet oxygen will disrupt the 
endothelial barriers  of the blood vessels and this destruction will initiate an aggregation of 
platelets that leads to thrombus formation (Park et al., 2006). The mode of action by which the 
photothrombosis model causes ischemic injury is one of the main reasons why this approach 
is used in studying the cellular and molecular changes after stroke (Labat-gest and Tomasi, 
2013). Photothrombosis mimics the stroke occurring in the human brain by means of platelet 
aggregation and the formation of blood clots, which affects the blood distribution during stroke 
(Lee et al., 2011). Like the novel artery occlusion technique such as middle cerebral artery 
occlusion, photothrombosis shares the main inflammatory responses after stroke (Schroeter et 
al., 2002). However, unlike the artery occlusion, photothrombosis precisely causes damage in 
the region of interest. Thus, it eliminates the lesion variability in comparison to artery occlusion 
(Windle et al., 2006).  
In addition, photothrombosis surgeries do not require extensive surgical expertise (Labat-gest 
and Tomasi, 2013). The simple execution is considered as another main advantage of using 
this technique. Another main advantage for using photothrombosis is that this technique is 
suitable to be performed on multiple transgenic mice strains. Other classical approaches have 
been reported to induce a higher rate of mortality in certain lines (Labat-gest and Tomasi, 
2013). On the other hand, using photothrombosis in penumbral regional studies is invalid, as 
the existence of this area is extremely limited and, in some cases, does not exist (Labat-gest 
and Tomasi, 2013). In addition, photothrombosis can be only used to study stroke in the 
superficial cortical layers and not the deep sub-cortical regions of the brain (Labat-gest and 




in the region of interest, the motor cortex. It allows investigation of the neuroprotective or 
therapeutic ability of an agent and its ability to promote functional recovery after a stroke (Park 
et al., 2006). 
4.2.4 The motor cortex as the region of interest 
In this experiment, the coordinates for targeting the motor cortex were based on the mouse 
brain atlas (Paxinos and Franklin, 2019). Photothrombosis in the mouse motor cortex is a 
reliable technique to produce a consistent size of stroke and causes long-term deficits 
accompanied with a same level of recovery (Overman et al., 2012). The associated axonal 
sprouting in the premotor cortex can be indicative of the recovery of the motor cortex. The new 
axonal sprouting was investigated by the injection of the BDA into the premotor cortex. The 
primary motor cortex affecting the overlapping representation of the forelimbs and the 
hindlimbs was targeted (Morandell and Huber, 2017). The produced lesion in the target area is 
considered to be small in comparison to other classical methods such as artery occlusion or the 
use of hypoxia to induce ischemic injury. However, it well represents the stroke produced in 
humans (Labat-gest and Tomasi, 2013). Stroke induced in the primary motor cortex of the 
mouse will not produce an abundant motor skills deficit unless tested by specialised tests such 
as the grid walking and cylinder tasks (Clarkson et al., 2011). Grid and cylinder tests were 
chosen based on the frequency used in literature (Clarkson et al., 2011; Overman et al., 2012). 
Choosing the most appropriate behavioural test is essential to detect the neurological deficit 
caused by a lesion in the area of interest (Schaar et al., 2010). It is important that the behavioural 
tests are compatible with the nature of the lesion. In motor cortex stroke as in this experiment, 
it was necessary to choose behavioural tests that are sensitive for motor and sensory deficits 
(Schaar et al., 2010). Grid and cylinder tasks had shown a potential sensitivity in relation to 
this study. In addition, after unilateral induction of stroke in the primary motor cortex, the 
animals have a significant behavioural asymmetry in that they prefer to use the limb ipsilateral 
to the lesion in comparison to the contralateral limb. This is due to what is known as 
decussation, which is the crossing over of the descending corticospinal pathways at the level 
of the medulla oblongata (Haines and Mihailoff, 2018). This allows investigation of the 
functional improvement in the usage of the affected limb (Forgie et al., 1996).  In this 
experiment, a contralateral neurological deficit was evidenced by the increase of foot slips 




4.3 Biological Considerations 
4.3.1 Systemic versus local treatment with epothilone D 
Animals which received epothilone D infused in a gel, showed - to a very limited degree - a 
reduction of foot faults in comparison to animals that received normal saline-infused gel. 
However, this reduction cannot be considered as a significant change after 8 weeks of the study 
(Fig. 3.3). The gel was designed to allow direct targeting to the periinfarct cortex. Yet, the 
reduction in the foot-faults following 5nM of epothilone D still failed to produce a marked 
reduction in this measured parameter. Five nanomoles was chosen based on in vitro studies 
showing the favourable effect of epothilone D in neuronal cell cultures (Brizuela et al., 2015). 
In pharmacological studies, the plasma half-life of epothilone D was reported in human and 
other animal species including dogs, mice and rats. In mice, the half-life of epothilone D was 
reported to be 16.3 minutes for 1µg/mL and it was elevated to 47.9 minutes for 100µg/mL 
doses (Wang et al., 2005). In addition, the protein binding property for epothilone D ranges 
from 93-99.4% in humans and dogs (Wang et al., 2005). As well, pharmacological studies 
showed that epothilone D has a rapid distribution -linked to plasma concentration curves- and 
slower elimination (Konner et al., 2012). Nevertheless, a study showed that after a single 
intraperitoneal injection of 3 mg/kg epothilone D mice maintained a detectable level in the 
brain tissue for 10 days (Brunden et al., 2010). Also, as discussed below, the glial scar may act 
as a boundary for axonal sprouting and will also minimize the penetration of the infused gel 
into the adjacent cortical areas, minimising the effect of epothilone D in supporting the 
cytoskeleton structure of the growing axons outside the glial scar. For these reasons, systemic 
treatment with epothilone D is likely to have maintained a longer phase of effect with better 
distribution throughout the area of interest of the brain cortex, enhancing the axonal sprouting. 
In regard to axonal sprouting, systemic administration of epothilone D showed a significant 
change in the number of sprouted axons and a change in the direction of the sprouting (Fig. 
3.11). The growth cones use cytoskeleton mechanics to advance to its target. This advancement 
requires stable MTs to penetrate through the domains of the growth cone, but not over-stable 
to permit growth cone steering towards the cues (Tanaka and Kirschner, 1991). The ability for 
a neuron to extend its axon can be considered as therapeutic mechanism to compensate the 
inability to regenerate. However, this effect was not evident in local treatment with epothilone 





4.3.2 Epothilone D systemic treatment did not restore motor skills to the same level as sham 
controls 
Systemic treatment with epothilone D was effective in rescuing contralateral function after 
focal stroke, compared to treatment with vehicle, but it did not restore motor skills to the same 
level as sham controls (Fig. 3.1). In an attempt to obtain a better outcome using intraperitoneal 
injection of epothilone D, a higher dose must be considered. In a few studies in vivo, it was 
proven that 3 mg/kg epothilone D can induce a better outcome in comparison with lower doses 
(Brunden et al., 2010; Sandner et al., 2018; Xiong et al., 2019). In addition, a higher dose is 
expected to be more effective for the reasons mentioned in Section 4.3.1, including the 
dependency of the plasma half-life of epothilone D on the dose, as well as the availability in 
the brain tissue after the injection.  
4.4 Future Directions 
 
4.4.1 Different doses of epothilone D  
Studying a multiple dose effect of epothilone D via a local and systemic route is also necessary. 
In this study only one dose of 1.5 mg/kg was delivered in a systemic route and a dose of 5 nM 
was delivered in a local route by using hydrogel. The use of higher doses simultaneously in 
either cohorts is suggested. Including a higher dose will allow evaluation of the dependency of 
axonal sprouting on the drug concentration. It is already proven that a high dose of epothilone 
(e.g, 70 times the dosage used in this experiment), as used in cancer treatment, induces a 
retraction in the growth cones in vitro (Brizuela et al., 2015). However, the optimal dosage of 
epothilone D that promotes optimal sprouting after a focal stroke has not been determined yet. 
For instance, a higher dose should be tested in the same setup. If the higher dose fails to promote 
functional recovery or worsen the outcome, lower concentrations must be considered. On the 
contrary, if the higher dose succeeded to establish a favourable significant difference, it means 
that the dosage used in this experiment could be considered as an insufficient dose. Testing a 
lower dose can be considered as important as higher dose assessment. In locally delivered 
epothilone D, cells treated with 100 nM epothilone D showed a decrease in the number of 
sprouts and the length of those sprouts (Brizuela et al., 2015). However, the same study 
demonstrated that 1 nM epothilone D induced the highest numbers of sprouts reflected in the 
length of the sprouting axons (Brizuela et al., 2015). Therefore, evaluating a lower dose of 
epothilone D in a local route is believed to be essential as an optimisation for the local approach.  
Recently, hydrogels containing polymers have been used to directly target the periinfarct cortex 




treatment (Nih et al., 2016). However, hydrogels have not been used extensively in brain injury 
treatment. The release profile for each drug should be studied independently, as the soft nature 
of the materials used in hydrogel tends to degrade faster than anticipated (Nih et al., 2016). 
4.4.2 Effect of epothilone D on the size of the stroke and on microtubules 
For the purposes of optimizing this experiment, further testing should be taken in consideration 
for both delivery routes. Firstly, stroke size quantification should be performed to determine 
the effect of epothilone D on the stroke size on animals treated with 5 nM locally, and 1.5mg/kg 
systemically. This should be carried out by treatment with epothilone D and stroke size to be 
calculated after 7 days of stroke (Clarkson et al., 2011). 
Secondly, a group of sham animals which did not receive any treatment should to be included 
as a control group in systemic and local treatment groups. This will enable comparison of 
treated animals with a normal brain and to achieve a more robust conclusion.  
Thirdly, studying the effect of epothilone D on the post-translational modification of MTs 
should be investigated. Histological sections for animals that received treatment after stroke 
should be evaluated by immunohistochemical staining for different post-translational 
modifications such as acetylation, tyrosination and detyrosination (Killinger and Moszczynska, 
2016) using commercially available primary antibodies targeting the mentioned modifications. 
This will allow a better understanding of the mechanism of action of epothilone D and its effect 
on axonal sprouting after injury. This assessment should be performed 7, 14, 21 and 28 days 
after stroke, as the deterioration of symptoms will be reduced from 7 days after the insult, and 
it is important to investigate the mechanism by which the stabilisation of MTs can affect stroke 
recovery over time. As well as, during the period from 7-28 days after stroke, there is a marked 
increase in axonal sprouting followed by synaptic marker proteins, suggesting the increased 
process in axonal growth that can be investigated extensively during this period (Carmichael, 
2006). 
4.4.3 Effect of epothilone D on other aspects of brain plasticity 
As described in Chapter 1, axonal sprouting is only a part of brain plasticity. Other parts, 
including the formation of new connections (synaptogenesis) and angiogenesis, should be 
investigated. This can be performed by detecting the presence of new synapses or the 
recruitment of older ones to perform a new function. Immunohistochemistry for synaptic 




quantification of synaptic anatomy in the region of interest (Lin et al., 2016). In addition, 
studying the distribution of NMDA and AMPA receptors could lead to an evaluation of the 
activation of silent synapses after a stroke. Silent synapses have NMDA, but not AMPA 
receptors, yet they do not respond to physiological input from the presynaptic neurons. In this 
aspect, activation of silent synapses plays a major role in brain plasticity as these circuits can 
be activated to be recruited to perform a specified function (Atwood and Wojtowicz, 1999). 
Active excitatory synapses usually contain both NMDA and AMPA receptors (Atwood and 
Wojtowicz, 1999). Hence a colocalised signal can be detected using immunohistochemistry. 
Changes in the location of silent synapses after the use of epothilone D could provide evidence 
that the stabilisation of MTs can have a major effect on brain plasticity. 
4.4.4 Effect of epothilone D on the glial scar 
Another variable to be assessed is the formation of a glial scar formed around the stroke (Zhang 
et al., 2018). As indicated in Chapter 1, epothilones stabilize the MTs, which is necessary for 
normal cell functions such as division and migration. Stabilizing the MTs can limit a cell’s 
ability to divide and migrate, which may affect astrogliosis and its activation process (Ruschel 
and Bradke, 2018). This in turn will affect the thickness of scar formed around the ischemic 
insult. In addition, systemic delivery of the drug can also limit the ability for the diapedesis of 
white blood cells (Clark et al., 2020), reducing the inflammatory response to the stroke. The 
reduction of the inflammatory response after stroke can be both beneficial and harmful for 
axonal sprouting. It was explained previously that certain inflammatory molecules can be 
neuroprotective, and others can be neurotoxic (see Section 1.5). However, to determine the 
effect of epothilone D on the production of inflammatory molecules, and the effect on axonal 
sprouting, further investigations must be carried out. 
4.5 Conclusions 
In this thesis, the role of epothilone D on functional recovery and axonal sprouting in a mouse 
model of ischemic stroke was investigated. It was hypothesised that weekly injections of 
epothilone D systemically could induce axonal sprouting and promote functional recovery. The 
results were significant among the subject groups, which is consistent with the previous testing 
for this class of drugs in other brain disorders. Specifically, 1.5 mg/kg body weight of 
epothilone D was proven to promote sufficient axonal sprouting that was also reflected in the 




epothilone D using a hydrogel. Thus, the current evidence from this thesis supports the use of 
systemic delivery of the MT stabiliser epothilone D.  
Yet, there is a huge gap between the pre-clinical and clinical trials in the field of stroke. 
Therefore, the results of the epothilone D effect on axonal sprouting and overall performance 
of the tested animals should be subjected to further optimization and investigations before 
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6.1 Appendix A 
 



















Two-way ANOVA analysis for the total number of the footsteps on the grid walking test. The 
data are from the contralateral and ipsilateral forepaw combined for the sham groups 
(shamEsys and shamVeh). In these two groups, total footsteps decreased significantly over 
time (F (1,12) = 20.48, p=0.0007). There was no significant effect of treatment group (F (1, 12) = 
3.34, p=0.92) and a no significant treatment group x time interaction (F (1, 12) = 0.16, p=0.7), 
indicating that the changes in footsteps over time were equivalent between the two groups. 
Data are presented as mean ± SEM. * p<0.05, ** p<0.01 (1st vs. 8th week comparison). 
 
